cyan20180630

0001437749-18-015344.txt : 20180813 0001437749-18-015344.hdr.sgml : 20180813 20180813160501 ACCESSION NUMBER: 0001437749-18-015344 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180813 DATE AS OF CHANGE: 20180813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYANOTECH CORP CENTRAL INDEX KEY: 0000768408 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 911206026 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-14602 FILM NUMBER: 181012283 BUSINESS ADDRESS: STREET 1: 73-4460 QUEEN KAAHUMANU HWY STREET 2: SUITE 102 CITY: KAILUA KONA STATE: HI ZIP: 96740 BUSINESS PHONE: 8083261353 MAIL ADDRESS: STREET 1: 73-4460 QUEEN KAAHUMANU HWY STREET 2: SUITE 102 CITY: KAILUA-KONA STATE: HI ZIP: 96740 10-Q 1 cyan20180630_10q.htm FORM 10-Q cyan20180630_10q.htm

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For Quarterly Period Ended June 30, 2018

☐

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Transition Period From to

Commission File Number 0-14602

CYANOTECH CORPORATION

(Exact name of registrant as specified in its charter)

NEVADA		91-1206026
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification Number)

73-4460 Queen Kaahumanu Hwy. #102, Kailua-Kona, HI 96740

(Address of principal executive offices)

(808) 326-1353

(Registrant’s telephone number)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐		Accelerated filer ☐

Non-accelerated filer ☐		Smaller reporting company ☒
(Do not check if a smaller reporting company)
		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of common shares outstanding as of August 10, 2018:

Title of Class		Shares Outstanding
Common stock - $0.02 par value		5,788,887

Table of Contents

CYANOTECH CORPORATION

FORM 10-Q

INDEX

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets as of June 30, 2018 and March 31, 2018 (unaudited)	3
	Condensed Consolidated Statements of Operations for the three months ended June 30, 2018 and 2017 (unaudited)	4
	Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2018 and 2017 (unaudited)	5
	Notes to Condensed Consolidated Financial Statements (unaudited)	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19
Item 4.	Controls and Procedures	19
PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	21
Item 1A	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults upon Senior Securities	21
Item 5.	Other Information	21
Item 6.	Exhibits	22
SIGNATURES		23

Table of Contents

PART 1. FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

CYANOTECH CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(Unaudited)

	June 30, 2018			March 31, 2018
ASSETS
Current assets:
Cash	$	935		$	1,329
Accounts receivable, net of allowance for doubtful accounts of $27 at June 30, 2018 and $27 at March 31, 2018		2,804			2,664
Inventories, net		9,487			9,034
Prepaid expenses and other current assets		593			590
Total current assets		13,819			13,617

Equipment and leasehold improvements, net		15,432			15,734
Restricted cash		—			65
Other assets		280			291
Total assets	$	29,531		$	29,707

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Line of credit	$	1,250		$	500
Current maturities of long-term debt		660			655
Customer deposits		300			133
Accounts payable		3,735			3,527
Accrued expenses		1,000			892
Total current liabilities		6,945			5,707

Long-term debt, less current maturities		5,636			5,790
Other long-term liabilities		98			103
Total liabilities		12,679			11,600

Commitments and contingencies

Stockholders’ equity:
Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding		—			—
Common stock of $0.02 par value, authorized 50,000,000 shares; 5,788,887 shares issued and outstanding at June 30, 2018 and 5,772,032 at March 31, 2018		116			115
Additional paid-in capital		32,070			32,051
Accumulated deficit		(15,334	)		(14,059	)
Total stockholders’ equity		16,852			18,107
Total liabilities and stockholders’ equity	$	29,531		$	29,707

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

CYANOTECH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

	Three Months Ended June 30,
	2018			2017

NET SALES	$	7,145		$	8,809
COST OF SALES		5,309			5,206
Gross Profit		1,836			3,603

OPERATING EXPENSES:
General and administrative		1,372			1,352
Sales and marketing		1,423			1,489
Research and development		208			142
Total operating expenses		3,003			2,983

(Loss) income from operations		(1,167	)		620

Interest expense, net		130			108

(Loss) income before income tax		(1,297	)		512

INCOME TAX (BENEFIT) EXPENSE		(22	)		11

NET (LOSS) INCOME	$	(1,275	)	$	501

NET (LOSS) INCOME PER SHARE:
Basic	$	(0.22	)	$	0.09
Diluted	$	(0.22	)	$	0.09

SHARES USED IN CALCULATION OF NET (LOSS) INCOME PER SHARE:
Basic		5,785			5,685
Diluted		5,785			5,719

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

CYANOTECH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands)

(Unaudited)

	Three Months Ended June 30,
	2018			2017

CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$	(1,275	)	$	501
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization		475			479
Amortization of debt issue costs and other assets		19			15
Share-based compensation expense		34			31
Net (increase) decrease in assets:
Accounts receivable		(140	)		(484	)
Inventories		(453	)		(9	)
Prepaid expenses and other assets		(3	)		138
Net increase (decrease) in liabilities:
Customer deposits		167			(40	)
Accounts payable		208			(534	)
Accrued expenses		108			130
Deferred rent and other liabilities		(5	)		(17	)
Net cash (used in) provided by operating activities		(865	)		210

CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in equipment and leasehold improvements		(173	)		(56	)
Net cash used in investing activities		(173	)		(56	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Net draws (payments) on line of credit		750			(111	)
Principal payments on long-term debt		(141	)		(130	)
Payments on capitalized leases		(16	)		(21	)
Withholding on restricted stock unit vesting		(32	)		—
Proceeds from stock options exercised		18			—
Net cash provided by (used in) financing activities		579			(262	)

Net decrease in cash and restricted cash		(459	)		(108	)

Cash and restricted cash at beginning of period		1,394			1,407

Cash at end of period	$	935		$	1,299

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest	$	103		$	104
Income taxes	$	—		$	—

RECONCILIATION OF CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD:
Cash	$	1,329	$	1,407
Restricted cash		65		—
Total cash and restricted cash at beginning of period	$	1,394	$	1,407

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

CYANOTECH CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2018
(Unaudited)

1.	SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (SEC). These interim condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to present fairly the Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations, and Condensed Consolidated Statements of Cash Flows for the periods presented in accordance with GAAP. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full fiscal year. The Condensed Consolidated Balance Sheet as of March 31, 2018 was derived from the audited consolidated financial statements. These condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended March 31, 2018, contained in the Company’s annual report on Form 10-K as filed with the SEC on June 15, 2018.

The accompanying condensed consolidated financial statements include the accounts of Cyanotech Corporation and its wholly owned subsidiary, Nutrex Hawaii, Inc. (“Nutrex Hawaii” or “Nutrex”, collectively the “Company”). All significant intercompany balances and transactions have been eliminated in consolidation.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of any contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the periods reported. Management reviews these estimates and assumptions periodically and reflects the effect of revisions in the period that they are determined to be necessary. Actual results could differ from those estimates and assumptions.

Liquidity

As of June 30, 2018, the Company had cash of $0.9 million and working capital of $6.9 million compared to $1.3 million and $7.9 million, respectively, at March 31, 2018. On August 30, 2016, the Credit Agreement, which the Company and First Foundation Bank (the Bank) entered into on June 3, 2016, became effective. The Credit Agreement allows the Company to borrow up to $2.0 million on a revolving basis. At June 30, 2018, the Company had borrowed $1.25 million and had $0.75 million available on the line. The line of credit was renewed on August 30, 2017 and will expire on August 30, 2018. The Company intends to renew or replace it with another line of credit on or before the expiration date.

As of June 30, 2018, the Company had $6.2 million of term loans payable to the Bank that require the payment of principal and interest monthly through August 2032. Pursuant to the term loans, the Company is subject to annual financial covenants, customary affirmative and negative covenants and certain subjective acceleration clauses. As of March 31, 2018, the Company was in compliance with these financial covenants.

Funds generated by operating activities and available cash continue to be the Company’s most significant sources of liquidity for working capital requirements, debt service and funding of maintenance levels of capital expenditures. Based upon the Company’s fiscal year 2019 operating plan and related cash flow projections and the Company’s projected consolidated financial position as of March 31, 2019, cash flows expected to be generated by operating activities and available financing are expected to be sufficient to fund the Company’s operations for at least the next twelve months, and the Company’s current ratio is expected to be in compliance with the annual term loan covenant requirement as of March 31, 2019. However, no assurances can be provided that the Company will achieve its operating plan and cash flow objectives for the next fiscal year or its projected consolidated financial position as of March 31, 2019. Such estimates are subject to change based on future results and such change could cause future results to vary significantly from expected results.

Revenue Recognition

The Company records revenue based on the five-step model which includes: (1) identifying the contract with the customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations; and (5) recognizing revenue when the performance obligations are satisfied. Substantially all of the Company’s revenue is generated by fulfilling orders for the purchase of our micro algal nutritional supplements to retailers, wholesalers, or direct to consumers via online channels, with each order considered to be a distinct performance obligation. These orders may be formal purchase orders, verbal phone orders, e-mail orders or orders received online. Shipping and handling activities for which the Company is responsible under the terms and conditions of the order are not accounted for as performance obligations but as fulfillment costs. These activities are required to fulfill the Company’s promise to transfer the goods and are expensed when revenue is recognized. The impact of this policy election is insignificant as it aligns with our current practice.

Revenue is measured as the net amount of consideration expected to be received in exchange for fulfilling a performance obligation. The Company has elected to exclude sales, use and similar taxes from the measurement of the transaction price. The impact of this policy election is insignificant, as it aligns with our current practice. The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, which includes costs for trade promotion programs, coupons, returns and early payment discounts. Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. The Company reviews and updates these estimates at the end of each reporting period and the impact of any adjustments are recognized in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, the Company considers the customer's ability and intent to pay that amount of consideration when it is due. Payment of invoices is due as specified in the underlying customer agreement, typically 30 days from the invoice date, which occurs on the date of transfer of control of the products to the customer.

Revenue is recognized at the point in time that the control of the ordered products is transferred to the customer. Generally, this occurs when the product is delivered, or in some cases, picked up from one of our distribution centers by the customer.

Customer contract liabilities consist of customer deposits received in advance of fulfilling an order and are shown separately on the consolidated balance sheets. During the three-month periods ended June 30, 2018 and June 30, 2017, the Company recognized $112,000 and $45,000, respectively, of revenue from deposits that were included in contract liabilities as of March 31, 2018 and March 31, 2017, respectively. The Company’s contracts have a duration of one year or less and therefore, the Company has elected the practical expedient of not disclosing revenues allocated to partially unsatisfied performance obligations.

The following table represents revenue disaggregated by product in the three months ended June 30, 2018 and June 30, 2017 (in thousands):

	Three months ended June 30, 2018
	Astaxanthin		Spirulina		Total
Packaged products	$	5,095	$	1,068	$	6,163
Bulk products		263		719		982
Total	$	5,358	$	1,787	$	7,145

	Three months ended June 30, 2017
	Astaxanthin		Spirulina		Total
Packaged products	$	5,505	$	1,927	$	7,432
Bulk products		221		1,156		1,377
Total	$	5,726	$	3,083	$	8,809

Table of Contents

Recently Adopted Accounting Pronouncements

In May 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-09, Compensation-Stock Compensation (Topic 718) Scope of Modification Accounting ("ASU No. 2017-09"). ASU No. 2017-09 will clarify and reduce both (i) diversity in practice and (ii) cost and complexity when applying the guidance in Topic 718, to a change to the terms and conditions of a share-based payment award. This guidance became effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years. The amendments in this ASU are applied prospectively to awards modified on or after the adoption date. The Company adopted this standard as of April 1, 2018 with no impact on its consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash” (“ASU No. 2016-18”). This update addresses the fact that diversity exists in the classification and presentation of changes in restricted cash on the statement of cash flows under Topic 230, Statement of Cash Flows. ASU No. 2016-18 became effective for public companies for the fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted this standard as of April 1, 2018 by using the retrospective method, which required reclassification of restricted cash in the accompanying consolidated statement of cash flows as of the beginning of the period for the three months ended June 30, 2018.

In August 2016, FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU No. 2016-15”). This ASU clarifies and provides specific guidance on eight cash flow classification issues that are not currently addressed by current GAAP and thereby reduces the current diversity in practice. ASU No. 2016-15 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017. The Company adopted this standard as of April 1, 2018 with no impact on its consolidated financial statements and related disclosures.

In May 2014, the FASB issued their converged standard on revenue recognition, Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”("ASU No. 2014-09"), updated in December 2016 with the release of ASU 2016-20. This standard outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods and services in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. In August 2015, the FASB issued ASU No 2015-14 “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date," which deferred the effective date of ASU No. 2014-09 to annual reporting periods beginning after December 15, 2017.

The new revenue standard is required to be applied either retrospectively to each prior reporting period presented or prospectively with the cumulative effect of initially applying the standard recognized at the date of the initial application, supplemented with certain disclosures related to the effect of adoption on previously reported amounts, if any (the modified retrospective method). The Company adopted the standard on April 1, 2018 for contracts that were not completed before the adoption date, using the modified retrospective method. The Company has evaluated the effect of the standard and concluded it is not material to the timing or amount of revenues or expenses recognized in the Company’s historical consolidated financial statements. As a result, the Company has concluded that the application of the standard does not have a material effect that requires a retrospective adjustment to any previously reported amounts in the Company’s historical consolidated financial statements for reporting disclosure purposes.

Table of Contents

Recently Issued Accounting Pronouncements

In July 2018, the FASB issued ASU 2018-10 “Codification Improvements to Topic 842, Leases” (“ASU No. 2018-02”). This ASU affects narrow aspects of the guidance issued in the amendments in ASU No. 2016-02 including those regarding residual value guarantees, rate implicit in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases under Topic 840, transition guidance for modifications to leases previously classified as direct financing or sales-type leases under Topic 840, transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions. The Company is currently evaluating the impact this ASU will have on its implementation of ASU No. 2016-02.

In June 2018, the FASB issued ASU 2018-07 “Compensation - Stock Compensation (Topic 718)” (“ASU No. 2018-07”): Improvements to Nonemployee Share-Based Payment Accounting. This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU No. 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact this new guidance will have on its financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU No. 2016-02”). The principle objective of ASU No. 2016-02 is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet. ASU No. 2016-02 continues to retain a distinction between finance and operating leases but requires lessees to recognize a right-of-use asset representing its right to use the underlying asset for the lease term and a corresponding lease liability on the balance sheet for all leases with terms greater than twelve months. ASU No. 2016-02 is effective for fiscal years and interim periods beginning after December 15, 2018. Early adoption of ASU No. 2016-02 is permitted. Entities are required to apply the amendments at the beginning of the earliest period presented using a modified retrospective approach. This guidance is applicable to the Company’s fiscal year beginning April 1, 2019. In July 2018, the FASB issued ASU No. 2018-11, "Leases (Topic 842): Targeted Improvements," which provides an additional transition method that permits changes to be applied by means of a cumulative-effect adjustment recorded in retained earnings as of the beginning of the fiscal year of adoption. The Company has started the assessment process by evaluating the population of leases under the revised definition of what qualifies as a leased asset, and expects to have the assessment completed by March 2019. The Company is the lessee under various agreements for facilities and equipment that are currently accounted for as operating and capital leases. The Company expects this guidance will have a material impact on its consolidated balance sheets due to the recognition of lease rights and obligations as assets and liabilities, respectively. The Company does not expect this guidance to have a material effect on its consolidated results of operations and cash flows.

2.	INVENTORIES

Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method. Inventories consist of the following:

	June 30, 2018		March 31, 2018
	(in thousands)
Raw materials	$	371	$	410
Work in process		3,301		2,602
Finished goods		5,663		5,878
Supplies		152		144
Inventories, net	$	9,487	$	9,034

The Company recognizes abnormal production costs, including fixed cost variances from normal production capacity, as an expense in the period incurred. Abnormal costs related to spirulina production of $250,000 were charged to cost of sales for the quarter ended June 30, 2018. There were no abnormal production costs for the quarter ended June 30, 2017. Non-inventoriable fixed costs related to spirulina production of $125,000 were charged to cost of sales for the quarter ended June 30, 2018. Non-inventoriable fixed costs related to spirulina production of $9,000 were charged to cost of sales for the quarter ended June 30, 2017.

Table of Contents

3.	EQUIPMENT AND LEASEHOLD IMPROVEMENTS, NET

Equipment and leasehold improvements are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives for equipment and furniture and fixtures, or the shorter of the land lease term or estimated useful lives for leasehold improvements as follows:

	Years
Equipment		3	to	10
Furniture and fixtures		3	to	7
Leasehold improvements		10	to	25

Equipment and leasehold improvements consist of the following:

	June 30, 2018			March 31, 2018
	(in thousands)
Equipment	$	18,114		$	17,935
Leasehold improvements		14,287			14,248
Furniture and fixtures		348			348
		32,749			32,531
Less accumulated depreciation and amortization		(17,821	)		(17,346	)
Construction-in-progress		504			549
Equipment and leasehold improvements, net	$	15,432		$	15,734

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. Recoverability of these assets is measured by a comparison of the carrying amount to forecasted undiscounted future cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future cash flows, then an impairment charge is recognized to the extent that the carrying amount exceeds the asset’s fair value. Management has determined no asset impairment existed as of June 30, 2018 and March 31, 2018, respectively.

4.	LINE OF CREDIT

On August 30, 2016, the Revolving Credit Agreement (the “Credit Agreement”), which the Company and First Foundation Bank (“the Bank”) entered into on June 3, 2016, became effective after the Company and the Bank received the necessary approvals from the State of Hawaii to secure the lien on the Company’s leasehold property in Kona, Hawaii. The Credit Agreement allows the Company to borrow up to $2,000,000 on a revolving basis. Borrowings under the Credit Agreement bear interest at the Wall Street Journal prime rate (5.00% at June 30, 2018) + 2%, floating. The Credit Agreement includes various covenants as defined in the Credit Agreement. The Credit Agreement also contains standard acceleration provisions in the event of a default by the Company. At June 30, 2018, the Company had borrowed $1,250,000 under the Credit Agreement and had $750,000 available on the line. The line of credit will be subject to renewal upon expiration on August 30, 2018.

5.	ACCRUED EXPENSES

Accrued expenses consist of the following:

	June 30, 2018		March 31, 2018
	(in thousands)
Wages, commissions, bonus and profit sharing	$	807	$	707
Rent and utilities		69		69
Other accrued expenses		124		116
Total accrued expenses	$	1,000	$	892

6.	LONG-TERM DEBT

Long-term debt consists of the following:

	June 30, 2018			March 31, 2018
	(in thousands)
Long-term debt	$	6,520		$	6,678
Less current maturities		(660	)		(655	)
Long-term debt, excluding current maturities		5,860			6,023
Less unamortized debt issuance costs		(224	)		(233	)
Total long-term debt, net of current maturities and unamortized debt issuance costs	$	5,636		$	5,790

Table of Contents

Term Loans

The Company executed a loan agreement with a lender providing for $2,500,000 in aggregate credit facilities (the “2015 Loan”) secured by substantially all the Company’s assets, pursuant to a Term Loan Agreement dated July 30, 2015 (the “2015 Loan Agreement”). The 2015 Loan Agreement is evidenced by a promissory note in the amount of $2,500,000, the repayment of which is partially guaranteed under the provisions of a United States Department of Agriculture (“USDA”) Rural Development Guarantee program. The proceeds of the 2015 Loan were used to pay off a $500,000 short term note payable that matured on September 18, 2015, and to acquire new processing equipment and leasehold improvements at the Company’s Kona, Hawaii facility.

The provisions of the 2015 Loan Agreement require the payment of principal and interest until its maturity on September 1, 2022, the obligation fully amortizes over seven (7) years. Interest on the 2015 Loan accrues on the outstanding principal balance at an annual variable rate equal to the published Wall Street Journal prime rate (5.00% at June 30, 2018) plus 2.0% and is adjustable on the first day of each calendar quarter and fixed for that quarter. At no time shall the annual interest rate be less than 6.00%. The 2015 Loan has a prepayment penalty of 5% for any prepayment made prior to the first anniversary of the date of the 2015 Loan Agreement, which penalty is reduced by 1% each year thereafter until the fifth anniversary of such date, after which there is no prepayment penalty. The balance under the 2015 Loan was $1,644,000 and $1,726,000 at June 30, 2018 and March 31, 2018, respectively.

The 2015 Loan includes a one-time origination and guaranty fee totaling $113,900 and an annual renewal fee payable in the amount of 0.50% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year, beginning December 31, 2015. The USDA has guaranteed 80% of all amounts owing under the 2015 Loan. The Company is subject to financial covenants and customary affirmative and negative covenants.

The Company executed a loan agreement with a lender providing for $5,500,000 in aggregate credit facilities (the “Loan”) secured by substantially all the Company’s assets, including a mortgage on the Company's interest in its lease at the National Energy Laboratory of Hawaii Authority, pursuant to a Term Loan Agreement dated August 14, 2012 (the “Loan Agreement”). The Loan Agreement is evidenced by promissory notes in the amounts of $2,250,000 and $3,250,000, the repayment of which is partially guaranteed under the provisions of a USDA Rural Development Guarantee. The proceeds of the Loan have been used to acquire new processing equipment and leasehold improvements at the Company’s Kona, Hawaii facility.

The provisions of the Loan required the payment of interest only for the first 12 months of the term; thereafter, and until its maturity on August 14, 2032, the obligation fully amortizes over nineteen (19) years. Interest on the Loan accrues on the outstanding principal balance at an annual variable rate equal to the published Wall Street Journal prime rate (5.00% at June 30, 2018) plus 1.0% and is adjustable on the first day of each calendar quarter and fixed for that quarter. At no time shall the annual interest rate be less than 5.50%. The balance under this Loan was $4,596,000 and $4,648,000 at June 30, 2018 and March 31, 2018, respectively.

The Loan includes a one-time origination and guaranty fees totaling $214,500 and an annual renewal fee payable in the amount of 0.25% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year, beginning December 31, 2012. The USDA has guaranteed 80% of all amounts owing under the Loan. The Company is subject to financial covenants and customary affirmative and negative covenants.

On October 6, 2017, the Company entered into an Equipment Finance Agreement (the “Equipment Agreement”) with a lender, which provides up to $175,000 of financing for equipment. The interest rate on this loan is 4.75%. The provisions of the Equipment Agreement require the payment of principal and interest until its maturity on October 31, 2022, the obligation fully amortizes over five (5) years. The balance under this loan was $149,000 and $156,000 at June 30, 2018 and March 31, 2018, respectively.

Capital Leases

The Company has three capital leases providing for $278,000 in equipment, secured by the equipment financed. The capital leases mature at various dates between May 2019 and March 2021 and are payable in 60 equal monthly payments, except for one which is payable in 36 equal monthly payments. The interest rates under these capital leases range from 4.18% to 12.90%. The aggregate balance under these leases was $131,000 and $148,000 at June 30, 2018 and March 31, 2018, respectively.

Future principal payments under the term loan and capital lease agreements as of June 30, 2018 are as follows:

Payments Due	(in thousands)
Next 12 Months	$	660
Year 2		684
Year 3		685
Year 4		716
Year 5		398
Thereafter		3,377
Total principal payments	$	6,520

Table of Contents

7.	OPERATING LEASES

The Company leases facilities, equipment and land under operating leases expiring through 2035. The land lease provides for contingent rentals in excess of minimum rental commitments based on a percentage of the Company’s sales. Management has accrued for the estimated contingent rent as of June 30, 2018.

Future minimum lease payments under all non-cancelable operating leases at June 30, 2018 are as follows:

Payments Due	(in thousands)
Next 12 Months	$	628
Year 2		611
Year 3		537
Year 4		533
Year 5		397
Thereafter		3,741
Total minimum lease payments	$	6,447

8.	OTHER COMMITMENTS AND CONTINGENCIES

From time to time, the Company may be involved in litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. The Company believes that it currently is not a party to any legal proceedings or claims which, individually or in aggregate, would have a material effect on its consolidated financial position, results of operations or cash flows.

9.	SHARE-BASED COMPENSATION

The Company accounts for share-based payment arrangements using fair value. If an award vests or becomes exercisable based on the achievement of a condition other than service, such as for meeting certain performance or market conditions, the award is classified as a liability. Liability-classified awards are remeasured to fair value at each balance sheet date until the award is settled. The Company currently has no liability-classified awards. Equity-classified awards, including grants of employee stock options, are measured at the grant-date fair value of the award and are not subsequently remeasured unless an award is modified. The cost of equity-classified awards is recognized in the statement of operations over the period during which an employee is required to provide the service in exchange for the award, or the vesting period. All of the Company’s stock options are service-based awards, and because the Company’s stock options are “plain vanilla,” as defined by the U.S. Securities and Exchange Commission in Staff Accounting Bulletin No. 107, they are reflected only in equity and compensation expense accounts.

As of June 30, 2018, the Company had two equity-based compensation plans: the 2016 Equity Incentive Plan (the 2016 Plan) and the 2014 Independent Director Stock Option and Restricted Stock Grant Plan (the “2014 Directors Plan”). The Company has also issued stock options, which remain outstanding as of June 30, 2018, under two equity-based compensation plans which have expired according to their terms: the 2005 Stock Option Plan (the “2005 Plan”) and the 2004 Independent Director Stock Option and Stock Grant Plan (the “2004 Directors Plan”). These plans allowed the Company to award stock options and shares of restricted common stock to eligible employees, certain outside consultants and independent directors. No additional awards will be issued under the 2005 Plan or the 2004 Directors Plan.

On August 25, 2016, the Company’s shareholders approved the 2016 Plan as a successor to the 2005 Plan, authorizing the Board of Directors to provide incentive to the Company’s officers, employees and certain independent consultants through equity based compensation in the form of stock options, restricted stock, restricted stock units, stock appreciation rights and other stock based awards (together, “Stock Awards”) and performance shares and performance units (together “Performance Awards”). Awards under the 2016 Plan are limited to the authorized amount of 1,300,000 shares, up to 600,000 of which are available for issuance in connection with Performance Awards and Stock Awards. As of June 30, 2018, there were 1,131,483 shares available for grant under the 2016 Plan.

On August 28, 2014, the Company’s shareholders approved the 2014 Directors Plan authorizing the Board of Directors to provide incentive to the Company’s independent directors through equity based compensation in the form of stock options and restricted stock. Awards under the 2014 Directors Plan are limited to the authorized amount of 350,000 shares. As of June 30, 2018, there were 231,623 shares available for grant under the 2014 Directors Plan.

Table of Contents

The following table presents shares authorized, available for future grant and outstanding under each of the Company’s plans:

	As of June 30, 2018
	Authorized		Available		Outstanding

2016 Plan		1,300,000		1,131,483		152,514
2014 Directors Plan		350,000		231,623		12,000
2005 Plan		—		—		437,400
2004 Directors Plan		—		—		12,000
Total		1,650,000		1,363,106		613,914

Stock Options

All stock option grants made under the equity-based compensation plans were issued at exercise prices no less than the Company’s closing stock price on the date of grant. Options under the 2005 Plan and 2014 Directors Plan were determined by the Board of Directors or the Compensation Committee of the Board of Directors in accordance with the provisions of the respective plans. The terms of each option grant include vesting, exercise, and other conditions are set forth in a Stock Option Agreement evidencing each grant. No option can have a life in excess of ten (10) years. The Company records compensation expense for employee stock options based on the estimated fair value of the options on the date of grant using the Black-Scholes option-pricing model. The model requires various assumptions, including a risk-free interest rate, the expected term of the options, the expected stock price volatility over the expected term of the options, and the expected dividend yield. Compensation expense for employee stock options is recognized ratably over the vesting term. Compensation expense recognized for options issued under all Plans was $18,000 and $15,000 for the three months ended June 30, 2018 and 2017, respectively. All stock-based compensation has been classified as general and administrative expense in the condensed consolidated statement of operations.

A summary of option activity under the Company’s stock plans for the three months ended June 30, 2018 is presented below:

Option Activity	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at March 31, 2018		589,400		$	4.06		4.9	$	675,300
Granted		—			—
Exercised		(6,000	)	$	2.85
Forfeited		(2,000	)	$	5.61
Outstanding at June 30, 2018		581,400		$	4.07		4.7	$	158,724
Exercisable at June 30, 2018		461,400		$	4.21		3.6	$	114,324

The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price optionees would have received if all options had been exercised on the last business day of the period indicated, based on the Company’s closing stock price of $3.90 for such day.

A summary of the Company’s non-vested options for the three months ended June 30, 2018 is presented below:

Nonvested Options	Shares		Weighted Average Grant-Date Fair Value
Nonvested at March 31, 2018		120,000	$	1.81
Granted		—		—
Vested		—		—
Forfeited		—		—
Nonvested at June 30, 2018		120,000	$	1.81

Table of Contents

The following table summarizes the weighted average characteristics of outstanding stock options as of June 30, 2018:

			Outstanding Options						Exercisable Options
Range of Exercise Prices			Number of Shares		Remaining Life (Years)		Weighted Average Price		Number of Shares		Weighted Average Price
$1.60	-	$3.70		166,800		5.1	$	3.06		91,800	$	2.82
$3.71	-	$4.42		239,100		4.5		3.83		194,100		3.83
$4.43	-	$5.40		95,000		4.9		5.00		95,000		5.00
$5.41	-	$7.08		80,500		4.4		5.77		80,500		5.77
Total stock options				581,400		4.7	$	4.07		461,400	$	4.21

The range of fair value assumptions related to options granted during the year ended March 31, 2018 were as follows:

	2018
Exercise Price	$	3.83
Volatility		51.91	%
Risk Free Rate		2.50	%
Vesting Period (years)		3.0
Forfeiture Rate		0.00	%
Expected Life (in years)		6.00
Dividend Rate		0	%

As of June 30, 2018, total unrecognized stock-based compensation expense related to all unvested stock options was $163,000, which is expected to be expensed over a weighted average period of 2.0 years.

Restricted Stock Units (“RSUs”)

RSUs are service-based awards granted to eligible employees under the 2016 Plan. Compensation expense recognized for RSUs issued under the 2016 Plan was $16,000 and $16,000 for the three months ended June 30, 2018 and 2017, respectively.

On April 5, 2018, 1,474 RSUs were awarded to employees of the Company. This award is valued at $5.25 per share, the closing market price of Cyanotech common stock on the grant date, and vests over a period of two years.

The following table summarizes information related to awarded RSUs:

Nonvested Restricted Stock Units	Shares			Weighted Average Grant Price
Nonvested restricted stock units at March 31, 2018		39,675		$	3.89
Granted		1,474			5.25
Vested		(7,670	)		3.92
Forfeited		(965	)		4.29
Nonvested restricted stock units at June 30, 2018		32,514		$	3.93

As of June 30, 2018, total unrecognized stock-based compensation expense related to unvested restricted stock units was $110,000, which is expected to be expensed over a weighted average period of 1.8 years.

Subsequent to June 30, 2018, 22,449 restricted stock units were granted from the 2016 Plan to employees and officers of the Company.

10.

INCOME TAXES

On December 22, 2017 H.R. 1, originally known as the Tax Cuts and Jobs Act, (the “Tax Act”) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from 34% to 21% effective January 1, 2018. The Company will compute its income tax expense for the March 31, 2019 fiscal year using a Federal Tax Rate of 21%. The 21% Federal Tax Rate will apply to fiscal years ending March 31, 2019 and each year thereafter. The Company has completed the accounting for the income tax effects of the Tax Act as of March 31, 2018 and has determined that the amount identified as provisional in the quarter ended December 31, 2018 was a materially correct amount. As a result, no measurement period adjustments have been recorded.

We utilize our estimated annual effective tax rate to determine our provision (benefit) for income taxes for interim periods. The income tax provision (benefit) is computed by multiplying the estimated annual effective tax rate by the year to date pre-tax book income (loss). We recorded income tax benefit of ($22,000) and income tax expense of $11,000 for the three months ended June 30, 2018 and 2017, respectively. Our effective tax rate was 1.7% and 2.1% for the quarters ended June 30, 2018 and June 30, 2017, respectively. The effective tax rate for the three months ended June 30, 2018 differs from the statutory rate of 21% as a result of state taxes (net of federal benefit) and the net change in valuation allowance against the net deferred tax asset the Company believes is not more likely than not to be realized.

Table of Contents

The Company is subject to taxation in the United States and six state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities. As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (“uncertain tax positions”) and therefore may require the Company to pay additional taxes. Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events.

As of June 30, 2018, there was no liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its consolidated condensed statements of operations, which is consistent with the recognition of these items in prior reporting periods.

With few exceptions, the Company is no longer subject to U.S. federal, state, local, and non-U.S. income tax examination by tax authorities for tax years before 2013.

11.

EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share is computed on the basis of the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed on the basis of the weighted average number of common shares outstanding plus the potentially dilutive effect of outstanding stock options using the “treasury stock” method.

Reconciliations between the numerator and the denominator of the basic and diluted earnings (loss) per share computations for the three months ended June 30, 2018 and 2017 are as follows:

	Three Months Ended June 30, 2018
	Net Loss (Numerator)			Shares (Denominator)		Per Share Amount
	(in thousands)
Basic and diluted loss per share	$	(1,275	)		5,785	$	(0.22	)

	Three Months Ended June 30, 2017
	Net Income (Numerator)		Shares (Denominator)		Per Share Amount
	(in thousands)
Basic income per share	$	501		5,685	$	0.09
Effect of dilutive securities-Common stock options		—		34		—
Diluted income per share	$	501		5,719	$	0.09

Basic and diluted loss per share are the same in periods of a net loss, because common share equivalents are anti-dilutive when a net loss is recorded. Diluted earnings per share does not include the impact of common stock options totaling 120,000 and 0 for the three months ended June 30, 2018 and 2017, respectively, as the effect of their inclusion would be anti-dilutive. Restricted stock units become dilutive within the period granted and remain dilutive until the units vest and are issued as common stock. Diluted earnings per share does not include the impact of restricted stock units totaling 1,206 and 27,344 for the three months ended June 30, 2018 and 2017, as the effect of their inclusion would be anti-dilutive.

12.

CONCENTRATIONS OF RISK

Concentration of Accounts Receivable and Revenues

At June 30, 2018, 79% of the Company’s accounts receivable was comprised of two customer balances of 42% and 37%, respectively. At March 31, 2018, 77% of the Company’s accounts receivable was comprised of three customer balances of 49%, 17% and 11%, respectively. There were two customers with sales representing 31% and 27% of our total net sales for the three months ended June 30, 2018. There were two customers with sales representing 32% and 13% of our total net sales for the three months ended June 30, 2017.

13.

RELATED PARTY TRANSACTIONS AND BALANCES

During the three months ended June 30, 2018, the Company entered into a consulting agreement with an effective date of May 5, 2018 with a vendor that employs one of our independent directors. The Company’s independent director is not named in or involved in the performance of the consulting agreement. The contract amount is $120,000. $46,000 of the contract amount is reflected in general and administrative expense as of June 30, 2018 and no payments have been made against the contract during the three months ended June 30, 2018.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

This Report and other presentations made by Cyanotech Corporation (“CYAN”) and its subsidiary contain “forward-looking statements,” which include statements that are predictive in nature, depend upon or refer to future events or conditions, and usually include words such as “expects,” “anticipates,” “intends,” “plan,” “believes,” “predicts”, “estimates” or similar expressions. In addition, any statement concerning future financial performance, ongoing business strategies or prospects and possible future actions are also forward-looking statements. Forward-looking statements are based upon current expectations and projections about future events and are subject to risks, uncertainties and the accuracy of assumptions concerning CYAN and its subsidiary (collectively, the “Company”), the performance of the industry in which CYAN does business, and economic and market factors, among other things. These forward-looking statements are not guarantees of future performance. You should not place undue reliance on forward-looking statements.

Forward-looking statements speak only as of the date of the Report, presentation or filing in which they are made. Except to the extent required by the Federal Securities Laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Our forward-looking statements in this Report include, but are not limited to:

●

Statements relating to our business strategy;

●

Statements relating to our business objectives; and

●

Expectations concerning future operations, profitability, liquidity and financial resources.

These forward-looking statements are subject to risk, uncertainties and assumptions about us and our operations that are subject to change based on various important factors, some of which are beyond our control. The following factors, among others, could cause our financial performance to differ significantly from the goals, plans, objectives, intentions and expectations expressed in our forward-looking statements:

●

Environmental restrictions, soil and water conditions, levels of sunlight and seasonal weather patterns, particularly heavy rain, wind and other hazards;

●

Consumer perception of our products due to adverse scientific research or findings, publicity regarding nutritional supplements, litigation, regulatory investigations or other events, conditions and circumstances involving the Company which receive national media coverage;

●

Effects of competition, including tactics and locations of competitors and operating and market competition;

●

Demand for our products, the quantities and qualities thereof available for sale and levels of customer satisfaction, including significant unforeseen fluctuations in global demand for products similar to our products;

●

Our dependence on the experience, continuity and competence of our executive officers and other key employees;

●

The added risks associated with or attributed to the current local, national and world economic conditions, including but not limited to, the volatility of crude oil prices, inflation and currency fluctuations;

●

Changes in domestic and/or foreign laws, regulations or standards, affecting nutraceutical products or our methods of operation;

●

Access to available and reasonable financing on a timely basis;

●

The Company’s inability to generate enough revenues to meet its obligations or repay maturing indebtedness;

●

Failure of capital projects to operate as expected or meet expected results;

●

Changes in laws, corporate governance requirements and tax rates, regulations, accounting standards and the application to us or the nutritional products industry of new decisions by courts, regulators or other government authorities;

●

Legal costs associated with any legal proceedings, and the potential direct and indirect cost and other effects on our business or financial condition resulting from any legal proceedings.

●

Risk associated with the geographic concentration of our business;

●

Acts of war, terrorist incidents or natural disasters; and

●

Other risks or uncertainties described elsewhere in this Report and in other periodic reports previously and subsequently filed by us with the Securities and Exchange Commission.

Table of Contents

Overview:

We are a world leader in the production of high value natural products derived from microalgae. Incorporated in 1983, we are guided by the principle of providing beneficial, quality microalgal products for health and human nutrition in a sustainable, reliable and environmentally sensitive operation. We are GMP (Good Manufacturing Practices) certified by the Natural Products Association™, reinforcing our commitment to quality in our products, quality in our relationships (with our customers, suppliers, employees and the communities we live in), and quality of the environment in which we work. Our products include:

●

Hawaiian BioAstin® natural astaxanthin - a powerful dietary antioxidant shown to support and maintain the body’s natural inflammatory response, to enhance skin, and to support eye and joint health. It has expanding applications as a human nutraceutical and functional food ingredient; and

●

Hawaiian Spirulina Pacifica® - a nutrient-rich dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids

Microalgae are a diverse group of microscopic plants that have a wide range of physiological and biochemical characteristics and contain, among other things, high levels of natural protein, amino acids, vitamins, pigments and enzymes. Microalgae have the following properties that make commercial production attractive: (1) microalgae grow much faster than land grown plants, often up to 100 times faster; (2) microalgae have uniform cell structures with no bark, stems, branches or leaves, permitting easier extraction of products and higher utilization of the microalgae cells; and (3) the cellular uniformity of microalgae makes it practical to control the growing environment in order to optimize a particular cell characteristic. Efficient and effective cultivation of microalgae requires consistent light, warm temperatures, low rainfall and proper chemical balance in a very nutrient-rich environment, free of environmental contaminants and unwanted organisms. This is a challenge that has motivated us to design, develop and implement proprietary production and harvesting technologies, systems and processes in order to commercially produce human nutritional products derived from microalgae.

Our production of these products at the 90-acre facility on the Kona Coast of the island of Hawaii provides several benefits. We selected the Keahole Point location in order to take advantage of relatively consistent warm temperatures, sunshine and low levels of rainfall needed for optimal cultivation of microalgae. This location also offers us access to cold deep ocean water, drawn from an offshore depth of 2,000 feet, which we use in our Ocean-Chill Drying system to eliminate the oxidative damage caused by standard drying techniques and as a source of trace nutrients for microalgal cultures. The area is also designated a Biosecure Zone, with tight control of organisms allowed into the area and free of genetically modified organisms (GMO’s). We believe that our technology, systems, processes and favorable growing location generally permit year-round harvest of our microalgal products in a cost-effective manner.

Results of Operations

The following tables present selected consolidated financial data for each of the periods indicated ($ in thousands):

	Three Months Ended
	June 30, 2018			June 30, 2017
Net sales	$	7,145		$	8,809
Net sales decrease		(18.9	)%
Gross profit	$	1,836		$	3,603
Gross profit as % of net sales		25.7	%		40.9	%
Operating expenses	$	3,003		$	2,983
Operating expenses as % of net sales		42.0	%		33.9	%
Operating (loss) income	$	(1,167	)	$	620
Operating (loss) income as % of net sales		(16.3	)%		7.0	%
Income tax (benefit) expense	$	(22	)	$	11
Net (loss) income	$	(1,275	)	$	501

Net sales by product
Packaged sales
Astaxanthin packaged	$	5,095		$	5,505
Astaxanthin packaged sales decrease		(7.4	)%
Spirulina packaged	$	1,068		$	1,927
Spirulina packaged sales decrease		(44.6	)%
Total Packaged sales	$	6,163		$	7,432
Total Packaged sales decrease		(17.1	)%

Bulk sales
Astaxanthin bulk	$	263		$	221
Astaxanthin bulk sales increase		19.0	%
Spirulina bulk	$	719		$	1,156
Spirulina bulk sales decrease		(37.8	)%
Total Bulk sales	$	982		$	1,377
Total Bulk sales decrease		(28.7	)%

Table of Contents

Comparison of the Three Months Ended June 30, 2018 and 2017

Net Sales Net sales decreased 19% for the quarter, driven by a 17% decrease in our packaged products and a 29% decrease in bulk sales. The decrease in sales of our spirulina packaged products was the result of lower supply of spirulina, and the decrease in sales of our astaxanthin package products was the result of the quarterly variance year to year in the timing of international orders. The decrease in sales of our bulk products is primarily the result of the lack of available spirulina supply. International sales represented 20% of net sales for the current quarter compared to 27% for the same period last year.

Gross Profit Our gross profit as a percent of net sales decreased by 15.2 percentage points compared to the same period last year. In April 2018, we undertook a complete re-inoculation of our spirulina ponds. During the re-inoculation period, which was completed mid-May, there was no spirulina production. Since then, production has steadily increased and we have recently returned to normal production levels. The lower spirulina production levels in both Q4 of fiscal 2018 (-63% compared to Q4 of fiscal 2017) and in Q1 of the current fiscal year (-76% compared to Q1 of fiscal 2018) had a negative impact on the current quarter’s performance. In addition to decreased sales volume, the lower production levels resulted in a $1.1 million increase in costs in the current quarter and impacted gross margin by -14.9 points. Additionally, spirulina inventory on hand at the end of the quarter includes $0.6 million of higher overhead costs that will be amortized in the next quarter and negatively impact gross profit and margin.

Operating Expenses Operating expenses remained flat, increasing by 1% for the first quarter of fiscal 2019 compared to the same period in fiscal 2018.

Income Taxes We recorded an income tax benefit of $(22,000) in the current quarter with an effective tax rate of 1.7%, compared to an expense of $11,000 for the same period in fiscal 2018 with an effective tax rate of 2.1%. We continue to carry a full valuation allowance on our deferred tax asset.

Liquidity and Capital Resources

As of June 30, 2018, we had cash of $0.9 million and working capital of $6.9 million compared to $1.3 million and $7.9 million, respectively, at March 31, 2018. On August 30, 2016, the Credit Agreement, which we and First Foundation Bank (the Bank) entered into on June 3, 2016, became effective. The Credit Agreement allows us to borrow up to $2.0 million on a revolving basis. At June 30, 2018, we had borrowed $1.25 million and had $0.75 million available on the line. The line of credit is subject to renewal on August 30, 2018 and we are working with the Bank to renew the line of credit or replace it with another line of credit on or before the expiration date.

As of June 30, 2018, we had $6.2 million of term loans payable to the Bank that require the payment of principal and interest monthly through August 2032. Pursuant to the term loans, we are subject to annual financial covenants, customary affirmative and negative covenants and certain subjective acceleration clauses. We were in compliance with these financial covenants at March 31, 2018.

Funds generated by operating activities and available cash continue to be our most significant sources of liquidity for working capital requirements, debt service and funding of maintenance levels of capital expenditures. Based upon our fiscal year 2019 operating plan and related cash flow projections and our projected consolidated financial position as of March 31, 2019, cash flows expected to be generated by operating activities and available financing are expected to be sufficient to fund our operations for at least the next twelve months, and our current ratio is expected to be in compliance with the annual term loan covenant requirement as of March 31, 2019. However, no assurances can be provided that we will achieve our operating plan and cash flow objectives for the fiscal year ended March 31, 2019 or our projected consolidated financial position as of March 31, 2019. Such estimates are subject to change based on future results and such change could cause future results to vary significantly from expected results.

Cash Flows The following table summarizes our cash flows for the periods indicated ($ in thousands):

	Three months ended June 30
	2018			2017
Total cash (used in) provided by:
Operating activities	$	(865	)	$	210
Investing activities		(173	)		(56	)
Financing activities		579			(262	)

(Decrease) increase in cash	$	(459	)	$	(108	)

Cash used in operating activities for the three months ended June 30, 2018 was the result of a net loss, excluding non-cash charges, of $0.8 million and an increase in working capital of $0.1 million.

Table of Contents

Cash used in investing activities for the three months ended June 30, 2018 includes costs for leasehold improvements and equipment acquisitions at our Kona facility.

Cash provided by financing activities for the three months ended June 30, 2018 includes a $0.8 million increase in our line of credit balance, offset by $0.2 million in principal payments on debt in the normal course of business.

Sources and Uses of Capital

At June 30, 2018, our working capital was $6.9 million, a decrease of $1.0 million compared to March 31, 2018. The decrease is due primarily to the increase in short term debt.

Our results of operations and financial condition can be affected by numerous factors, many of which are beyond our control and could cause future results of operations to fluctuate materially as it has in the past. Future operating results may fluctuate as a result of changes in sales volumes to our largest customers, weather patterns, increased competition, increased materials, nutrient and energy costs, government regulations and other factors beyond our control.

A significant portion of our expense levels are relatively fixed, so the timing of increases in expenses is based in large part on forecasts of future sales. If net sales are below expectations in any given period, the adverse impact on results of operations may be magnified by our inability to adjust spending quickly enough to compensate for the sales shortfall. We may also choose to reduce prices or increase spending in response to market conditions, which may have a material adverse effect on financial condition and results of operations.

Based upon our current operating plan, analysis of our consolidated financial position and projected future results of operations, we believe that our operating cash flows, cash balances, and working capital will be sufficient to finance current operating requirements, debt service requirements, and routine planned capital expenditures, for the next twelve (12) months.

Outlook

This outlook section contains a number of forward-looking statements, all of which are based on current expectations. Actual results may differ materially.

Our strategic direction has been to position the Company as a world leader in the production and marketing of high-value natural products from microalgae. We are vertically aligned, producing raw materials in the form of microalgae processed at our 90-acre facility in Hawaii, and integrating those raw materials into finished products. In fiscal 2019, our primary focus is on building our consumer brands, increasing our astaxanthin production volume and improving the consistency of our production for both astaxanthin and spirulina. We will continue to put emphasis on our Nutrex Hawaii consumer products to introduce them to a broader consumer market, and leverage our experience and reputation for quality, building nutritional brands which promote health and well-being. The foundation of our nutritional products is naturally cultivated Hawaiian Spirulina Pacifica® in powder and tablet form; and BioAstin® Hawaiian Astaxanthin® antioxidant in extract and softgel caplet form. Information about our Company and our products can be viewed at www.cyanotech.com and www.nutrex-hawaii.com. Consumer products can also be purchased online at www.nutrex-hawaii.com.

We are focused on sustainability of production levels in order to promote growth in our astaxanthin and spirulina product lines. We will continue to improve and expand these lines to meet the demand of consumers. Our recent re-inoculation of our spirulina ponds was a necessary step toward sustaining long-term production levels. We will continue to promote the nutritional superiority of Hawaiian grown microalgae to maintain and expand market share. Significant sales variability between periods and even across several periods can be expected based on historical results.

Gross profit margin percentages going forward will be impacted by production volumes and continued pressure on input costs and greater competition in the market place. This could cause margins to decline in future periods. We will continue to focus on higher margin consumer products that promote health and well-being. We are dedicated to continuous improvements in process and production methods to stabilize and increase production levels for the future.

Producing the highest quality microalgae is a complex biological process which requires balancing numerous factors including microalgal strain variation, temperature, acidity, nutrient and other environmental considerations, some of which are not within our control. An imbalance or unexpected event can occur resulting in production levels below normal capacity. The allocation of fixed production overheads (such as depreciation, rent and general insurance) to inventories is determined based on normal production capacity. When our production volumes are below normal capacity limits, certain fixed production overhead costs cannot be inventoried and are recorded immediately in cost of sales. In addition, when production costs exceed historical averages, we evaluate whether such costs are one-time-period charges or an ongoing component of inventory cost.

Table of Contents

To manage our cash resources effectively, we will continue to balance production in light of sales demand, minimizing the cost associated with build-ups in inventory when appropriate. We could experience unplanned cash outflows and may need to utilize other cash resources to meet working capital needs. A prolonged downturn in sales could impair our ability to generate sufficient cash for operations and minimize our ability to attract additional capital investment which could become necessary in order to expand facilities, enter into new markets or maintain optimal production levels.

Our future results of operations and the other forward-looking statements contained in this Outlook, in particular the statements regarding revenues, gross margin and capital spending, involve a number of risks and uncertainties. In addition to the factors discussed above, any of the following could cause actual results to differ materially: business conditions and growth in the natural products industry and in the general economy; changes in customer order patterns; changes in demand for natural products in general; changes in weather conditions; changes in health and growing conditions of our astaxanthin and spirulina products; competitive factors, such as increased production capacity from competing spirulina and astaxanthin producers and the resulting impact, if any, on world market prices for these products; government actions and increased regulations both domestic and foreign; shortage of manufacturing capacity; and other factors beyond our control. Risk factors are discussed in detail in Part II, Item 1A of this quarterly report and in Part I, Item 1A of our Form 10-K report for the year ended March 31, 2018.

We believe that our technology, systems, processes and favorable growing location generally permit year-round harvest of our microalgal products in a cost-effective manner. However, previously experienced imbalances in the highly complex biological production systems, together with volatile energy costs and rapidly changing world markets, suggest a need for continuing caution with respect to variables beyond our reasonable control. Therefore, we cannot, and do not attempt to, provide any definitive assurance with regard to our technology, systems, processes, location, or cost-effectiveness.

Off-Balance Sheet Arrangements

As of June 30, 2018, we had no off-balance sheet arrangements or obligations.

Impact of Inflation

Inflationary factors such as increases in the costs of materials and labor directly affect the Company's operations. Most of the Company's leases provide for cost-of-living adjustments and require it to pay for insurance and maintenance expenses, all of which are subject to inflation. Additionally, the Company’s future lease cost for new facilities may include potentially escalating costs of real estate and construction. There is no assurance that the Company will be able to pass on increased costs to its customers.

Depreciation expense is based on the historical cost to the Company of its fixed assets, and is therefore potentially less than it would be if it were based on current replacement cost. While property and equipment acquired in prior years will ultimately have to be replaced at higher prices, it is expected that replacement will be a gradual process over many years.

Critical Accounting Policies and Estimates

Our critical accounting policies and estimates are disclosed in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended March 31, 2018 filed with the SEC on June 15, 2018. In the three months ended June 30, 2018, there were changes to the application of critical accounting policies previously disclosed in our most recent Annual Report on Form 10-K related to the adoption of ASU 2014-09 on April 1, 2018, as described below.

Revenue Recognition

Item 3. Quantitative and Qualitative Disclosures about Market Risk

There have been no material changes to our market risk during the three months ended June 30, 2018. For additional information, refer to our Annual Report on Form 10-K for the year ended March 31, 2018.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our chief executive officer (“CEO”) and chief financial officer (“CFO”), we have evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15(d)-15(e) of the Exchange Act as of the end of the period covered by this Report. Based on that evaluation, our CEO and CFO have concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosures.

Management’s Report on Internal Control over Financial Reporting

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our management evaluated the effectiveness of our internal control over financial reporting as of June 30, 2018. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in “Internal Control - Integrated Framework” (2013 Framework). Based on that assessment, management concluded that our internal control over financial reporting was effective as of June 30, 2018.

Table of Contents

Changes to Internal Control Over Financial Reporting

On April 1, 2018, we adopted Topic 606 (see Note 1). We implemented internal controls to ensure we adequately evaluate our contracts and properly assess the impact of the new accounting standards on our condensed consolidated financial statements. Although adoption of the new revenue standard had no impact on April 1, 2018 retained earnings or financial statement activity for the quarter ended June 30, 2018, and is not expected to have a material impact on our ongoing financial statements, we implemented changes to our business processes related to revenue recognition and the control activities within them. The changes included training within management, as well as new processes for ongoing contract review and monitoring to ensure completeness and accuracy of the information for new disclosures.

There were no other changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarterly period ended June 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system no matter how well designed and implemented, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues within a company are detected.

The inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistakes. Controls can also be circumvented by the individual acts of some persons, or by collusion of two or more people. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

This Form 10-Q should be read in conjunction with Item 9A “Controls and Procedures” of the Company’s Form 10-K for the fiscal year ended March 31, 2018, filed June 15, 2018.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time the Company may become party to lawsuits and claims that arise in the ordinary course of business relating to employment, intellectual property, and other matters. There were no significant legal matters outstanding at June 30, 2018.

Item 1A. Risk Factors

For a discussion of the risk factors relating to our business, please refer to Part I, Item 1A of our Form 10-K for the year ended March 31, 2018, which is incorporated by reference herein.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits

a) The following exhibits are furnished with this report:

31.1	Certifications of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of August 13, 2018.

31.2	Certifications of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of August 13, 2018.

32	Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 signed as of August 13, 2018.

99.1	Press Release dated August 13, 2018.

101	The following financial statements from Cyanotech Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements.

Table of Contents

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CYANOTECH CORPORATION
	(Registrant)


August 13, 2018	By:	/s/ Mawae R. Morton
(Date)		Mawae R. Morton
		Chief Executive Officer; Director


August 13, 2018	By:	/s/ Jole E. Deal
(Date)		Jole E. Deal
		Vice President — Finance & Administration and CFO
		(Principal Financial and Accounting Officer)

Table of Contents

EXHIBIT INDEX

Exhibit Number		Description

31.1		Certifications of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of August 13, 2018.

31.2		Certifications of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 signed as of August 13, 2018.

32		Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 signed as of August 13, 2018.

99.1		Press Release dated August 13, 2018.

101		The following financial statements from Cyanotech Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv) Notes to Condensed Consolidated Financial Statements.

EX-31.1 2 ex_118923.htm EXHIBIT 31.1 ex_118923.htm

Exhibit 31.1

Certification Pursuant

To 18 U. S. C. Section 1350,

As Adopted Pursuant To

Section 302 of the Sarbanes-Oxley Act of 2002

I, Mawae R. Morton, Chief Executive Officer certify that:

I have reviewed this quarterly report on Form 10-Q of Cyanotech Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: August 13, 2018	/s/ Mawae R. Morton
	Mawae R. Morton
	Chief Executive Officer; Director

EX-31.2 3 ex_118924.htm EXHIBIT 31.2 ex_118924.htm

Exhibit 31.2

Certification Pursuant

To 18 U. S. C. Section 1350,

As Adopted Pursuant To

Section 302 of the Sarbanes-Oxley Act of 2002

I, Jole Deal, Chief Financial Officer certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Cyanotech Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: August 13, 2018	/s/ Jole E. Deal
	Jole E. Deal
	Vice President—Finance & Administration and CFO
	(Principal Financial and Accounting Officer)

EX-32 4 ex_118929.htm EXHIBIT 32 ex_118925.htm

Exhibit 32

Certification of CEO and CFO

Pursuant to 18 U.S.C. Section 1350,

As Adopted Pursuant to Section 906

of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Cyanotech Corporation (the “Company”) on Form 10-Q for the period ended June 30, 2018 (the “Report”) as filed with the Securities and Exchange Commission on the date hereof, each of the undersigned certifies that:

1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act (15 U.S.C. 78m or 78o (d)); and

2)	The information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of the Company.

Date: August 13, 2018	/s/ Mawae R. Morton
	Mawae R. Morton
	Chief Executive Officer; Director


Date: August 13, 2018	/s/ Jole E. Deal
	Jole E. Deal
	Vice President—Finance & Administration and CFO
	(Principal Financial and Accounting Officer)

EX-99.1 5 ex_118986.htm EXHIBIT 99.1 ex_118986.htm

Exhibit 99.1

News Release											Contact: Bruce Russell
											(310) 346-6131
											brussell@cyanotech.com

Cyanotech Reports Financial Results for the First Quarter of Fiscal Year 2019

KAILUA KONA, Hawaii (August 13, 2018) — Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, announced financial results for the first quarter of fiscal year 2019, ended June 30, 2018.

First Quarter Fiscal 2019

For the first quarter of fiscal 2019 compared to the first quarter of fiscal 2018, net sales were $7,145,000 compared to $8,809,000. Gross profit was $1,836,000, with gross profit margin of 25.7%, compared to gross profit of $3,603,000 and gross profit margin of 40.9%. Operating loss was ($1,167,000) compared to operating income of $620,000. Net loss was ($1,275,000) or ($0.22) per diluted share, compared to net income of $501,000 or $0.09 per diluted share.

Commenting on the first quarter fiscal 2019 results (changes shown vs. the first quarter of fiscal 2018), Cyanotech’s Chief Executive Officer, Mawae Morton, said:

“Cyanotech's results for the quarter reflect the impact of a spirulina production shutdown and re-inoculation that was required during this time period. The re-inoculation process limited spirulina supply which impacted us from both a cost and a sales standpoint. The lower spirulina production levels in both Q4 of fiscal 2018 (-63% compared to Q4 of fiscal 2017) and in Q1 of the current fiscal year (-76% compared to Q1 of fiscal 2018) had a negative impact on the current quarter's performance. In addition to a 14.7% decrease in sales volume, the lower production levels resulted in a $1.1 million increase in costs in the current quarter which reduced gross margin by -14.9 points. Additionally, spirulina inventory on hand at the end of the quarter includes $0.6 million of higher overhead costs that will be amortized in the next quarter and will negatively impact gross profit and margin. Despite the supply disruption, ongoing demand for our Hawaiian Spirulina remains strong.

"Net sales decreased 19% for the quarter, driven by a 17% decrease in our packaged products and a 29% decrease in bulk sales. 12% of the decrease in sales of our packaged products was the result of lower supply of spirulina, and 5% was due to the quarterly variance year to year in the timing of international orders for astaxanthin. The decrease in sales of our bulk products is primarily the result of the lack of available spirulina supply.

"We will continue to put emphasis on our Nutrex Hawaii consumer products to introduce them to a broader consumer market, improve consumer awareness of astaxanthin, leverage our experience and reputation for quality, and build nutritional brands which promote health and well-being.

Commenting on production, Gerald R. Cysewski, Ph.D., Cyanotech’s founder and Chief Scientific Officer, said, “In April 2018, we undertook a complete re-inoculation of our spirulina ponds. During the re-inoculation period, which was completed in mid-May, there was no spirulina production. For various reasons reported upon earlier, this re-inoculation took longer than previous such cultivation adjustments but the algae is now responding favorably and yielding more normal levels of production.

73-4460 Queen Kaahumanu Highway, #102 ~ Kailua-Kona, Hawaii 96740

(808) 326-1353 fax (808) 329-3597 ~ www.cyanotech.com

“In addition, increased activity of the Kilauea Volcano on the Island of Hawaii began May 3, 2018. Although the increased volcanic activity is located approximately 50 miles away from Cyanotech and has had minimal effect on the Company's production, during some wind patterns a light volcanic haze (VOG) blows over Cyanotech's facilities. VOG does not affect product quality but can reduce light levels by about 10% at ground level. Reduced light levels reduce growth of microalgae and can negatively impact production levels. We have not observed significant VOG related production issues to date, but we continue to monitor light levels and other growing conditions."

Trailing 12 Months

For the trailing 12 months ended June 30, 2018 compared to the trailing 12 months ended June 30, 2017, net sales were $32,451,000 compared to $33,529,000. Gross profit was $11,604,000, with gross profit margin of 35.8%, compared to $13,006,000 and 38.8%. Net loss was ($751,000) or ($0.13) per diluted share, compared to net loss of ($23,000) or ($0.00) per diluted share.

Please review the Company’s Form 10-Q for the period ended June 30, 2018 for more detailed information.

— Cyanotech will host a Skype broadcast at 9 p.m. EDT on Tuesday, August 14 to respond to questions about its operating results and other topics of interest. Interested parties are asked to submit questions to questions@cyanotech.com before 12 p.m. EDT on Tuesday, August 14. The Company will respond only to relevant questions relating to the Company’s first quarter fiscal 2019 financial performance, and will not be accepting any questions or comments during the broadcast.

To join the broadcast, please browse http://cyanotech.com/meet approximately five minutes prior to the start time.

About Cyanotech — Cyanotech Corporation, a world leader in microalgae technology for over 30 years, produces BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica®. These all natural, dietary ingredients and supplements leverage our experience and reputation for quality, building nutritional brands which promote health and well-being. The Company’s mission is to fulfill the promise of whole health through Hawaiian microalgae. Cyanotech’s BioAstin® offers superior antioxidant activity which supports skin, eye and joint health, as well as recovery from exercise*. Cyanotech's Spirulina products offer nutrition that supports cardiovascular health and immunity.* All Cyanotech products are produced from microalgae grown at our 90-acre facility in Kona, Hawaii using patented and proprietary technology and are Generally Recognized as Safe (GRAS) for use in food products. Cyanotech sells its products direct to consumers at retail locations in the United States and online at www.nutrex-hawaii.com and also distributes to dietary supplement, nutraceutical and cosmeceutical manufacturers and marketers. The Company is regulated by the FDA. Visit www.cyanotech.com for more information.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

73-4460 Queen Kaahumanu Highway, #102 ~ Kailua-Kona, Hawaii 96740

(808) 326-1353 fax (808) 329-3597 ~ www.cyanotech.com

“Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995 Besides statements of present fact and historical fact, this press release may contain forward-looking statements. Forward-looking statements relate to the future and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by forward-looking statements. We caution against relying on forward-looking statements. Important factors that could change actual, future results include: changes in sales levels to our largest customers, weather patterns in Hawaii, production problems, risks associated with new products, foreign exchange fluctuations, and availability of financing, as well as national and global political, economic, business, competitive, market and regulatory conditions. Other factors are more fully detailed in the Company’s annual Form 10-K filings with the Securities and Exchange Commission.

Financial Tables Follow: The following tables do not contain footnotes or other information contained in the Company’s Form 10-Q for the period ended June 30, 2018, which can be found on the Cyanotech website (www.cyanotech.com) under Investors>Investor Filings upon filing. As such the following Financial Tables are provided only as a guide and other factors are more fully detailed in the Company’s annual Form 10-K filings with the Securities and Exchange Commission.

73-4460 Queen Kaahumanu Highway, #102 ~ Kailua-Kona, Hawaii 96740

(808) 326-1353 fax (808) 329-3597 ~ www.cyanotech.com

CYANOTECH CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(Unaudited)

	June 30, 2018			March 31, 2018
ASSETS
Current assets:
Cash	$	935		$	1,329
Accounts receivable, net of allowance for doubtful accounts of $27 at June 30, 2018 and $27 at March 31, 2018		2,804			2,664
Inventories, net		9,487			9,034
Prepaid expenses and other current assets		593			590
Total current assets		13,819			13,617

Equipment and leasehold improvements, net		15,432			15,734
Restricted cash		—			65
Other assets		280			291
Total assets	$	29,531		$	29,707

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Line of credit	$	1,250		$	500
Current maturities of long-term debt		660			655
Customer deposits		300			133
Accounts payable		3,735			3,527
Accrued expenses		1,000			892
Total current liabilities		6,945			5,707

Long-term debt, less current maturities		5,636			5,790
Other long-term liabilities		98			103
Total liabilities		12,679			11,600

Commitments and contingencies

Stockholders’ equity:
Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding		—			—
Common stock of $0.02 par value, authorized 50,000,000 shares; 5,788,887 shares issued and outstanding at June 30, 2018 and 5,772,032 at March 31, 2018		116			115
Additional paid-in capital		32,070			32,051
Accumulated deficit		(15,334	)		(14,059	)
Total stockholders’ equity		16,852			18,107
Total liabilities and stockholders’ equity	$	29,531		$	29,707

73-4460 Queen Kaahumanu Highway, #102 ~ Kailua-Kona, Hawaii 96740

(808) 326-1353 fax (808) 329-3597 ~ www.cyanotech.com

CYANOTECH CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

	Three Months Ended June 30,
	2018			2017

NET SALES	$	7,145		$	8,809
COST OF SALES		5,309			5,206
Gross Profit		1,836			3,603

OPERATING EXPENSES:
General and administrative		1,372			1,352
Sales and marketing		1,423			1,489
Research and development		208			142
Total operating expenses		3,003			2,983

(Loss) income from operations		(1,167	)		620

Interest expense, net		130			108

(Loss) income before income tax		(1,297	)		512

INCOME TAX (BENEFIT) EXPENSE		(22	)		11

NET (LOSS) INCOME	$	(1,275	)	$	501

NET (LOSS) INCOME PER SHARE:
Basic	$	(0.22	)	$	0.09
Diluted	$	(0.22	)	$	0.09

SHARES USED IN CALCULATION OF NET (LOSS) INCOME PER SHARE:
Basic		5,785			5,685
Diluted		5,785			5,719

73-4460 Queen Kaahumanu Highway, #102 ~ Kailua-Kona, Hawaii 96740

(808) 326-1353 fax (808) 329-3597 ~ www.cyanotech.com

EX-101.INS 6 cyan-20180630.xml XBRL INSTANCE DOCUMENT 69000 69000 175000 P19Y 0.005 0.0025 0.8 0.8 P1Y 113900 214500 60 36 0.05 0.01 0.05 0.05 0.05 250000 0 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.5pt 0pt -38pt; text-align: justify; text-indent: 36pt;"><div style="display: inline; font-weight: bold;">Liquidity </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt; text-align: justify;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>the Company had cash of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.9</div> million and working capital of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.9</div> million compared to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.3</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7.9</div> million, respectively, at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018. </div>On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 30, 2016, </div>the Credit Agreement, which the Company and First Foundation Bank (the Bank) entered into on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 3, 2016, </div>became effective. The Credit Agreement allows the Company to borrow up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.0</div> million on a revolving basis. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>the Company had borrowed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.25</div> million and had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.75</div> million available on the line. The line of credit was renewed on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 30, 2017 </div>and will expire on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 30, 2018. </div>The Company intends to renew or replace it with another line of credit on or before the expiration date.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt; text-align: justify;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>the Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.2</div> million of term loans payable to the Bank that require the payment of principal and interest monthly through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2032. </div>Pursuant to the term loans, the Company is subject to annual financial covenants, customary affirmative and negative covenants and certain subjective acceleration clauses. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>the Company was in compliance with these financial covenants.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt; text-align: justify;">Funds generated by operating activities and available cash continue to be the Company’s most significant sources of liquidity for working capital requirements, debt service and funding of maintenance levels of capital expenditures. Based upon the Company’s fiscal year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> operating plan and related cash flow projections and the Company’s projected consolidated financial position as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>cash flows expected to be generated by operating activities and available financing are expected to be sufficient to fund the Company’s operations for at least the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months, and the Company’s current ratio is expected to be in compliance with the annual term loan covenant requirement as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019. </div>However, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurances can be provided that the Company will achieve its operating plan and cash flow objectives for the next fiscal year or its projected consolidated financial position as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019. </div>Such estimates are subject to change based on future results and such change could cause future results to vary significantly from expected results.</div></div></div> 6200000 1644000 1726000 4596000 4648000 5636000 5790000 125000 9000 2 3 2 2 2 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-; min-width: 700px;"> <tr> <td style="vertical-align:bottom;width:84%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td colspan="4" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:15%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Years</div> </td> <td style="vertical-align:middle;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="vertical-align:bottom;width:84%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Equipment</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3</div> </td> <td style="vertical-align:bottom;width:4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">to</div> </td> <td style="vertical-align:bottom;width:5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="vertical-align:bottom;width:84%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Furniture and fixtures</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3</div> </td> <td style="vertical-align:bottom;width:4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">to</div> </td> <td style="vertical-align:bottom;width:5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">7</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="vertical-align:bottom;width:84%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Leasehold improvements</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">10</div> </td> <td style="vertical-align:bottom;width:4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">to</div> </td> <td style="vertical-align:bottom;width:5%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">25</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of June 30, 201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Authorized</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Available</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2016 Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,131,483</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">152,514</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2014 Directors Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">350,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">231,623</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2005 Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">437,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2004 Directors Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,650,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,363,106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">613,914</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> 0 P3Y 600000 6900000 7900000 false --03-31 Q1 2019 2018-06-30 10-Q 0000768408 5788887 Yes Smaller Reporting Company Cyanotech Corp No No cyan

3735000

3527000

2804000

2664000

1000000

892000

807000

707000

17821000

17346000

32070000

32051000

18000

15000

16000

27000

19000

15000

120000

1206

27344

29531000

29707000

13819000

13617000

131000

148000

278000

935000

1329000

1407000

1394000

1407000

935000

1299000

-459000

-108000

0.02

50000000

5788887

5772032

5788887

5772032

116000

115000

0.79

0.42

0.37

0.77

0.49

0.17

0.11

0.31

0.27

0.32

0.13

504000

549000

112000

45000

5309000

5206000

300000

133000

0.02

0.01

0.055

0.06

0.0475

0.0418

0.129

P7Y

P5Y

224000

233000

475000

479000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: -18pt; text-align: center;">Three months ended June 30, 2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Astaxanthin</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Spirulina</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 43%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Packaged products</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,095</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,068</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Bulk products</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">263</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">719</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">982</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,358</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,787</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,145</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: -18pt; text-align: center;">Three months ended June 30, 2017</div> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Astaxanthin</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Spirulina</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 43%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Packaged products</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,505</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,927</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,432</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Bulk products</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">221</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,156</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,377</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,726</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,083</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,809</div></td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">SHARE-BASED COMPENSATION</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">The Company accounts for share-based payment arrangements using fair value. If an award vests or becomes exercisable based on the achievement of a condition other than service, such as for meeting certain performance or market conditions, the award is classified as a liability. Liability-classified awards are remeasured to fair value at each balance sheet date until the award is settled. The Company currently has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> liability-classified awards. Equity-classified awards, including grants of employee stock options, are measured at the grant-date fair value of the award and are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> subsequently remeasured unless an award is modified. The cost of equity-classified awards is recognized in the statement of operations over the period during which an employee is required to provide the service in exchange for the award, or the vesting period. All of the Company’s stock options are service-based awards, and because the Company’s stock options are “plain vanilla,” as defined by the U.S. Securities and Exchange Commission in Staff Accounting Bulletin <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">107,</div> they are reflected only in equity and compensation expense accounts.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt; text-align: justify;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> equity-based compensation plans: the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Equity Incentive Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan) and the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> Independent Director Stock Option and Restricted Stock Grant Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2014</div> Directors Plan”). The Company has also issued stock options, which remain outstanding as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>under <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> equity-based compensation plans which have expired according to their terms: the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2005</div> Stock Option Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2005</div> Plan”) and the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2004</div> Independent Director Stock Option and Stock Grant Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">“2004</div> Directors Plan”). These plans allowed the Company to award stock options and shares of restricted common stock to eligible employees, certain outside consultants and independent directors. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> </div>additional awards will be issued under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2005</div> Plan or the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2004</div> Directors Plan.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt; text-align: justify;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 25, 2016, </div>the Company’s shareholders approved the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan as a successor to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2005</div> Plan, authorizing the Board of Directors to provide incentive to the Company’s officers, employees and certain independent consultants through equity based compensation in the form of stock options, restricted stock, restricted stock units, stock appreciation rights and other stock based awards (together, “Stock Awards”) and performance shares and performance units (together “Performance Awards”). Awards under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan are limited to the authorized amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,300,000</div> shares, up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">600,000</div> of which are available for issuance in connection with Performance Awards and Stock Awards. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,131,483</div> shares available for grant under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt; text-align: justify;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 28, 2014, </div>the Company’s shareholders approved the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> Directors Plan authorizing the Board of Directors to provide incentive to the Company’s independent directors through equity based compensation in the form of stock options and restricted stock. Awards under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> Directors Plan are limited to the authorized amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">350,000</div> shares. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">231,623</div> shares available for grant under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> Directors Plan.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt; text-align: justify;">The following table presents shares authorized, available for future grant and outstanding under each of the Company’s plans:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of June 30, 201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Authorized</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Available</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 55%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2016 Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,131,483</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">152,514</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2014 Directors Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">350,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">231,623</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2005 Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">437,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2004 Directors Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,650,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,363,106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">613,914</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Stock Options</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">All stock option grants made under the equity-based compensation plans were issued at exercise prices <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> less than the Company’s closing stock price on the date of grant. Options under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2005</div> Plan and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> Directors Plan were determined by the Board of Directors or the Compensation Committee of the Board of Directors in accordance with the provisions of the respective plans. The terms of each option grant include vesting, exercise, and other conditions are set forth in a Stock Option Agreement evidencing each grant. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> option can have a life in excess of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>) years. The Company records compensation expense for employee stock options based on the estimated fair value of the options on the date of grant using the Black-Scholes option-pricing model. The model requires various assumptions, including a risk-free interest rate, the expected term of the options, the expected stock price volatility over the expected term of the options, and the expected dividend yield. Compensation expense for employee stock options is recognized ratably over the vesting term. Compensation expense recognized for options issued under all Plans was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$18,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively. All stock-based compensation has been classified as general and administrative expense in the condensed consolidated statement of operations.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">  </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">A summary of option activity under the Company’s stock plans for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> is presented below:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Option Activity</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average<br /> Exercise </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average<br /> Remaining<br /> Contractual<br /> Term (in</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">years)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate<br /> Intrinsic<br /> Value</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Outstanding at March 31, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">589,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.06</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">675,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.85</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.61</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Outstanding at June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">581,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.07</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">158,724</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Exercisable at June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">461,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.21</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114,324</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price optionees would have received if all options had been exercised on the last business day of the period indicated, based on the Company’s closing stock price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.90</div> for such day.  </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">A summary of the Company’s non-vested options for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> is presented below:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Nonvested Options</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average<br /> Grant-Date<br /> Fair Value</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">Nonvested at March 31, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">120,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.81</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 9pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;">Nonvested at June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">120,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.81</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">The following table summarizes the weighted average characteristics of outstanding stock options as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td colspan="3" style="vertical-align:bottom;width:42.1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:33.7%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Outstanding Options</div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:20.8%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Exercisable Options</div></div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> </tr> <tr> <td colspan="3" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:42.1%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Range of Exercise Prices</div> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9.9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Number<br /> of Shares</div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9.9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Remaining<br /> Life (Years)</div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9.9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Price</div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9.9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Number of<br /> Shares</div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:8.9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Price</div></div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="vertical-align:bottom;width:4.2%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">$1.60</div> </td> <td style="vertical-align:bottom;width:2%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">-</div> </td> <td style="vertical-align:bottom;width:36%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$3.70</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">166,800</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5.1</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$</div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3.06</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">91,800</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$</div> </td> <td style="vertical-align:bottom;width:8%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">2.82</div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="vertical-align:bottom;width:4.2%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">$3.71</div> </td> <td style="vertical-align:bottom;width:2%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">-</div> </td> <td style="vertical-align:bottom;width:36%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$4.42</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">239,100</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.5</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3.83</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">194,100</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:8%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3.83</div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="vertical-align:bottom;width:4.2%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">$4.43</div> </td> <td style="vertical-align:bottom;width:2%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">-</div> </td> <td style="vertical-align:bottom;width:36%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$5.40</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">95,000</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.9</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5.00</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">95,000</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:8%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5.00</div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="vertical-align:bottom;width:4.2%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">$5.41</div> </td> <td style="vertical-align:bottom;width:2%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">-</div> </td> <td style="vertical-align:bottom;width:36%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$7.08</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">80,500</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.4</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5.77</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">80,500</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:8%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5.77</div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td colspan="3" style="vertical-align:bottom;width:42.1%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Total stock options</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">581,400</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.7</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$</div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.07</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">461,400</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$</div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:8%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.21</div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">The range of fair value assumptions related to options granted during the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> were as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 85%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exercise Price</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.83</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">51.91</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Risk Free Rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.50</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Vesting Period (years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Forfeiture Rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Expected Life (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dividend Rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> total unrecognized stock-based compensation expense related to all unvested stock options was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$163,000,</div> which is expected to be expensed over a weighted average period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.0</div> years.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 15pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Restricted Stock Units (“RSUs”)</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt; text-align: justify;">RSUs are service-based awards granted to eligible employees under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan. Compensation expense recognized for RSUs issued under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt; text-align: justify;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 5, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,474</div> RSUs were awarded to employees of the Company. This award is valued at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.25</div> per share, the closing market price of Cyanotech common stock on the grant date, and vests over a period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> years.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">The following table summarizes information related to awarded RSUs:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Nonvested Restricted Stock Units</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average<br /> Grant Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:left;">Nonvested restricted stock units at March 31, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,675</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.89</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 36pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,474</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 36pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,670</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 36pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(965</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:left;">Nonvested restricted stock units at June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,514</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.93</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt; text-align: justify;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> total unrecognized stock-based compensation expense related to unvested restricted stock units was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$110,000,</div> which is expected to be expensed over a weighted average period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.8</div> years. </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">Subsequent to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,449</div> restricted stock units were granted from the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Plan to employees and officers of the Company.</div></div>

120000

-0.22

0.09

-0.22

0.09

0.017

0.021

0.21

163000

110000

P2Y

P1Y292D

1372000

1352000

1836000

3603000

-1297000

512000

-22000

11000

-22000

11000

208000

-534000

140000

484000

108000

130000

167000

-40000

-5000

-17000

453000

9000

3000

-138000

-130000

-108000

103000

104000

5663000

5878000

9487000

9034000

371000

410000

152000

144000

3301000

2602000

12679000

11600000

29531000

29707000

6945000

5707000

2000000

750000

1250000

500000

149000

156000

5860000

6023000

660000

655000

6520000

6678000

3377000

398000

716000

685000

684000

660000

579000

-262000

-173000

-56000

-865000

210000

-1275000

501000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.5pt; text-align: left; text-indent: -9pt;"><div style="display: inline; font-weight: bold;">Recently Adopted Accounting Pronouncements</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt; text-align: justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2017, </div>the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div><div style="display: inline; font-style: italic;"> Compensation-Stock Compensation (Topic </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div><div style="display: inline; font-style: italic;">) Scope of Modification Accounting </div>("ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09"</div>)<div style="display: inline; font-style: italic;">.</div> ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> will clarify and reduce both (i) diversity in practice and (ii) cost and complexity when applying the guidance in Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718,</div> to a change to the terms and conditions of a share-based payment award. This guidance became effective for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017 </div>and interim periods within those fiscal years. The amendments in this ASU are applied prospectively to awards modified on or after the adoption date. The Company adopted this standard as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div>with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impact on its consolidated financial statements. </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> “<div style="display: inline; font-style: italic;">Statement of Cash Flows (Topic </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230</div><div style="display: inline; font-style: italic;">): Restricted Cash” </div>(“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18”</div>)<div style="display: inline; font-style: italic;">.  </div>This update addresses the fact that diversity exists in the classification and presentation of changes in restricted cash on the statement of cash flows under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230,</div> <div style="display: inline; font-style: italic;">Statement of Cash Flows</div>. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> became effective for public companies for the fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017, </div>and interim periods within those fiscal years. The Company adopted this standard as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div>by using the retrospective method, which required reclassification of restricted cash in the accompanying consolidated statement of cash flows as of the beginning of the period for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018. </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2016, </div>FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> “<div style="display: inline; font-style: italic;">Statement of Cash Flows (Topic </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">230</div><div style="display: inline; font-style: italic;">)</div>: <div style="display: inline; font-style: italic;">Classification of Certain Cash Receipts and Cash Payments”</div> (“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15”</div>). This ASU clarifies and provides specific guidance on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">eight</div> cash flow classification issues that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> currently addressed by current GAAP and thereby reduces the current diversity in practice. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017. </div>The Company adopted this standard as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div>with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impact on its consolidated financial statements and related disclosures. </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;text-indent:36pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the FASB issued their converged standard on revenue recognition, Accounting Standards Update <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> “<div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div>)”</div>("ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09"</div>), updated in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2016 </div>with the release of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.</div> This standard outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods and services in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.  In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2015, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div> “<div style="display: inline; font-style: italic;">Revenue from Contracts with Customers (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div></div>): <div style="display: inline; font-style: italic;">Deferral of the Effective Date,</div>" which deferred the effective date of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> to annual reporting periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2017.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;">  </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">The new revenue standard is required to be applied either retrospectively to each prior reporting period presented or prospectively with the cumulative effect of initially applying the standard recognized at the date of the initial application, supplemented with certain disclosures related to the effect of adoption on previously reported amounts, if any (the modified retrospective method). The Company adopted the standard on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div>for contracts that were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> completed before the adoption date, using the modified retrospective method.  The Company has evaluated the effect of the standard and concluded it is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> material to the timing or amount of revenues or expenses recognized in the Company’s historical consolidated financial statements. As a result, the Company has concluded that the application of the standard does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material effect that requires a retrospective adjustment to any previously reported amounts in the Company’s historical consolidated financial statements for reporting disclosure purposes.</div> <div style=""></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.5pt 0pt -36pt; text-align: left; text-indent: 34.5pt;"> <div style="display: inline; font-weight: bold;">Recently Issued Accounting Pronouncements</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:7.5pt;margin-top:0pt;text-align:left;text-indent:34.5pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> “<div style="display: inline; font-style: italic;">Codification Improvements to Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842,</div> Leases</div>” (“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02”</div>).  This ASU affects narrow aspects of the guidance issued in the amendments in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> including those regarding residual value guarantees, rate implicit in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840,</div> transition guidance for modifications to leases previously classified as direct financing or sales-type leases under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840,</div> transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions.  The Company is currently evaluating the impact this ASU will have on its implementation of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02.</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:34.5pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07</div> “<div style="display: inline; font-style: italic;">Compensation - Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>)</div><div style="display: inline; font-style: italic;">”</div> (“ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07”</div>): Improvements to Nonemployee Share-Based Payment Accounting. This ASU expands the scope of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> to include share-based payment transactions for acquiring goods and services from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07</div> is effective for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018, </div>including interim periods within that fiscal year. Early adoption is permitted but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> earlier than an entity’s adoption date of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606.</div> The Company is currently evaluating the impact this new guidance will have on its financial statements and related disclosures.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 45pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 7.5pt 0pt -2pt; text-align: left; text-indent: 45pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> “<div style="display: inline; font-style: italic;">Leases (Topic </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div><div style="display: inline; font-style: italic;">)” </div>(<div style="display: inline; font-style: italic;">“</div>ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02”</div>). The principle objective of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> continues to retain a distinction between finance and operating leases but requires lessees to recognize a right-of-use asset representing its right to use the underlying asset for the lease term and a corresponding lease liability on the balance sheet for all leases with terms greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div> months. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> is effective for fiscal years and interim periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>Early adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> is permitted. Entities are required to apply the amendments at the beginning of the earliest period presented using a modified retrospective approach. This guidance is applicable to the Company’s fiscal year beginning <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2019. </div>In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> "<div style="display: inline; font-style: italic;">Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>): Targeted Improvements</div>," which provides an additional transition method that permits changes to be applied by means of a cumulative-effect adjustment recorded in retained earnings as of the beginning of the fiscal year of adoption. The Company has started the assessment process by evaluating the population of leases under the revised definition of what qualifies as a leased asset, and expects to have the assessment completed by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2019. </div>The Company is the lessee under various agreements for facilities and equipment that are currently accounted for as operating and capital leases. The Company expects this guidance will have a material impact on its consolidated balance sheets due to the recognition of lease rights and obligations as assets and liabilities, respectively. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect this guidance to have a material effect on its consolidated results of operations and cash flows.</div></div></div>

3003000

2983000

-1167000

620000

6447000

628000

397000

533000

537000

611000

3741000

124000

116000

280000

291000

98000

103000

32000

173000

56000

0.01

10000000

593000

590000

2500000

5500000

2250000

3250000

750000

-111000

18000

18114000

17935000

14287000

14248000

348000

32749000

32531000

15432000

15734000

P3Y

P10Y

P3Y

P7Y

P10Y

P25Y

46000

16000

21000

141000

130000

500000

208000

142000

65000

-15334000

-14059000

5095000

1068000

6163000

263000

719000

982000

5358000

1787000

7145000

5505000

1927000

7432000

221000

1156000

1377000

5726000

3083000

8809000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -45pt; text-indent: 45pt; text-align: justify;"><div style="display: inline; font-weight: bold;">Revenue Recognition</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt -45pt; text-indent: 45pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 45pt;">The Company records revenue based on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div>-step model which includes: (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) identifying the contract with the customer; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) identifying the performance obligations in the contract; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>) determining the transaction price; (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) allocating the transaction price to the performance obligations; and (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>) recognizing revenue when the performance obligations are satisfied. Substantially all of the Company’s revenue is generated by fulfilling orders for the purchase of our micro algal nutritional supplements to retailers, wholesalers, or direct to consumers via online channels, with each order considered to be a distinct performance obligation. These orders <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be formal purchase orders, verbal phone orders, e-mail orders or orders received online. Shipping and handling activities for which the Company is responsible under the terms and conditions of the order are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> accounted for as performance obligations but as fulfillment costs. These activities are required to fulfill the Company’s promise to transfer the goods and are expensed when revenue is recognized. The impact of this policy election is insignificant as it aligns with our current practice.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 45pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 45pt;">Revenue is measured as the net amount of consideration expected to be received in exchange for fulfilling a performance obligation. The Company has elected to exclude sales, use and similar taxes from the measurement of the transaction price.  The impact of this policy election is insignificant, as it aligns with our current practice. The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, which includes costs for trade promotion programs, coupons, returns and early payment discounts.  Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. The Company reviews and updates these estimates at the end of each reporting period and the impact of any adjustments are recognized in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, the Company considers the customer's ability and intent to pay that amount of consideration when it is due. Payment of invoices is due as specified in the underlying customer agreement, typically <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div> days from the invoice date, which occurs on the date of transfer of control of the products to the customer.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 45pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 45pt;">Revenue is recognized at the point in time that the control of the ordered products is transferred to the customer. Generally, this occurs when the product is delivered, or in some cases, picked up from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> of our distribution centers by the customer. </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 45pt;">Customer contract liabilities consist of customer deposits received in advance of fulfilling an order and are shown separately on the consolidated balance sheets. During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2017, </div>the Company recognized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$112,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$45,000,</div> respectively of revenue from deposits that were included in contract liabilities as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018</div><div style="display: inline; text-decoration: underline;"> </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017, </div>respectively. The Company’s contracts have a duration of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year or less and therefore, the Company has elected the practical expedient of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> disclosing revenues allocated to partially unsatisfied performance obligations.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 45pt;">The following table represents revenue disaggregated<div style="display: inline; text-decoration: underline;"> </div>by product in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2017 (</div>in thousands):</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 45pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: -18pt; text-align: center;">Three months ended June 30, 2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Astaxanthin</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Spirulina</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 43%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Packaged products</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,095</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,068</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Bulk products</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">263</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">719</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">982</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,358</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,787</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,145</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: -18pt; text-align: center;">Three months ended June 30, 2017</div> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Astaxanthin</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Spirulina</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Total</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 43%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Packaged products</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,505</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,927</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,432</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Bulk products</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">221</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,156</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,377</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,726</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,083</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,809</div></td> </tr> </table> </div></div></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended June 30, 201</div><div style="display: inline; font-weight: bold;">8</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Net </div><div style="display: inline; font-weight: bold;">Loss</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Numerator)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Denominator)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Per Share</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Amount</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(in thousands)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Basic and diluted loss per share</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,275</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,785</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended June 30, 201</div><div style="display: inline; font-weight: bold;">7</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Net </div><div style="display: inline; font-weight: bold;">Income</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Numerator)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Denominator)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Per Share</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Amount</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(in thousands)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Basic income per share</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">501</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,685</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.09</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Effect of dilutive securities-Common stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Diluted income per share</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">501</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,719</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.09</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-; min-width: 700px;"> <tr> <td colspan="3" style="vertical-align:bottom;width:42.1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:33.7%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Outstanding Options</div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:20.8%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Exercisable Options</div></div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> </tr> <tr> <td colspan="3" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:42.1%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Range of Exercise Prices</div> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9.9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Number<br /> of Shares</div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9.9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Remaining<br /> Life (Years)</div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9.9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Price</div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9.9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Number of<br /> Shares</div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:8.9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Price</div></div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="vertical-align:bottom;width:4.2%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">$1.60</div> </td> <td style="vertical-align:bottom;width:2%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">-</div> </td> <td style="vertical-align:bottom;width:36%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$3.70</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">166,800</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5.1</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$</div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3.06</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">91,800</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$</div> </td> <td style="vertical-align:bottom;width:8%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">2.82</div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="vertical-align:bottom;width:4.2%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">$3.71</div> </td> <td style="vertical-align:bottom;width:2%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">-</div> </td> <td style="vertical-align:bottom;width:36%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$4.42</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">239,100</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.5</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3.83</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">194,100</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:8%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3.83</div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="vertical-align:bottom;width:4.2%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">$4.43</div> </td> <td style="vertical-align:bottom;width:2%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">-</div> </td> <td style="vertical-align:bottom;width:36%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$5.40</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">95,000</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.9</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5.00</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">95,000</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:8%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5.00</div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td style="vertical-align:bottom;width:4.2%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">$5.41</div> </td> <td style="vertical-align:bottom;width:2%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;">-</div> </td> <td style="vertical-align:bottom;width:36%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$7.08</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">80,500</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.4</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5.77</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">80,500</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:8%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5.77</div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td colspan="3" style="vertical-align:bottom;width:42.1%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Total stock options</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">581,400</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.7</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$</div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.07</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:9%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">461,400</div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">$</div> </td> <td style="vertical-align:bottom;border-bottom:double 3px #000000;;width:8%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4.21</div> </td> <td style="vertical-align:bottom;width:0.5%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Option Activity</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted<br /> Average<br /> Exercise </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average<br /> Remaining<br /> Contractual<br /> Term (in</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">years)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate<br /> Intrinsic<br /> Value</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Outstanding at March 31, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">589,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.06</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">675,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.85</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.61</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 18pt;">Outstanding at June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">581,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.07</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">158,724</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;">Exercisable at June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">461,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.21</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114,324</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

1423000

1489000

34000

31000

P2Y

965

4.29

1474

22449

1474

5.25

39675

32514

152514

12000

437400

12000

613914

3.89

3.93

7670

3.92

3.83

0.5191

0.025

1300000

350000

1300000

350000

1650000

1131483

231623

1131483

1363106

461400

4.21

2000

675300

158724

589400

581400

4.06

4.07

2.85

5.61

1.60

3.71

4.43

5.41

91800

194100

95000

80500

461400

166800

239100

95000

80500

581400

3.70

4.42

5.40

7.08

3.90

P10Y

P6Y

114324

P3Y219D

120000

1.81

P4Y328D

P4Y255D

2.82

3.83

5.77

4.21

3.06

3.83

5.77

4.07

P5Y36D

P4Y182D

P4Y328D

P4Y146D

P4Y255D

6000

16852000

18107000

34000

5785000

5719000

5785000

5685000

Net of reserve for obsolescence of $1,000 and $5,000 at June 30, 2018 and March 31, 2018, respectively. Includes $373,000 of equipment under capital lease at March 31, 2018 and 2017 respectively, with accumulated amortization of $175,000 and $106,000, respectively. xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0000768408 cyan:TermLoanAgreementMaturingOnAugust142032Member 2012-08-14 2012-08-14 0000768408 cyan:TermLoanAgreementMaturingOnAugust142032Member srt:MinimumMember 2012-08-14 2012-08-14 0000768408 cyan:TermLoanAgreementPromissoryNoteOneMember 2012-08-14 2012-08-14 0000768408 cyan:TermLoanAgreementPromissoryNoteTwoMember 2012-08-14 2012-08-14 0000768408 cyan:The2015LoanAgreementMember 2015-07-01 2015-07-30 0000768408 2015-09-18 2015-09-18 0000768408 us-gaap:RevolvingCreditFacilityMember cyan:FirstFoundationBankMember us-gaap:PrimeRateMember 2016-08-30 2016-08-30 0000768408 2017-04-01 2017-06-30 0000768408 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0000768408 us-gaap:RestrictedStockUnitsRSUMember 2017-04-01 2017-06-30 0000768408 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0000768408 us-gaap:RestrictedStockUnitsRSUMember 2017-04-01 2017-06-30 0000768408 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-04-01 2017-06-30 0000768408 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cyan:CustomerNumber1Member 2017-04-01 2017-06-30 0000768408 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cyan:CustomerNumber2Member 2017-04-01 2017-06-30 0000768408 us-gaap:DepositAccountMember 2017-04-01 2017-06-30 0000768408 2017-04-01 2018-03-31 0000768408 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2017-04-01 2018-03-31 0000768408 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember cyan:CustomerNumber1Member 2017-04-01 2018-03-31 0000768408 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember cyan:CustomerNumber2Member 2017-04-01 2018-03-31 0000768408 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember cyan:CustomerNumber3Member 2017-04-01 2018-03-31 0000768408 2017-04-01 2018-06-30 0000768408 cyan:AstaxanthinMember 2017-04-01 2018-06-30 0000768408 cyan:BulkAstaxanthinMember 2017-04-01 2018-06-30 0000768408 cyan:BulkProductsMember 2017-04-01 2018-06-30 0000768408 cyan:BulkSpirulinaMember 2017-04-01 2018-06-30 0000768408 cyan:PackagedAstaxanthinMember 2017-04-01 2018-06-30 0000768408 cyan:PackagedProductsMember 2017-04-01 2018-06-30 0000768408 cyan:PackagedSpirulinaMember 2017-04-01 2018-06-30 0000768408 cyan:SpirulinaMember 2017-04-01 2018-06-30 0000768408 cyan:EquipmentFinanceAgreementMember 2017-10-06 2017-10-06 0000768408 2018-04-01 2018-06-30 0000768408 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000768408 us-gaap:RestrictedStockUnitsRSUMember 2018-04-01 2018-06-30 0000768408 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000768408 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2018-04-01 2018-06-30 0000768408 us-gaap:RestrictedStockUnitsRSUMember 2018-04-01 2018-06-30 0000768408 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-04-01 2018-06-30 0000768408 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember cyan:CustomerNumber1Member 2018-04-01 2018-06-30 0000768408 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember cyan:CustomerNumber2Member 2018-04-01 2018-06-30 0000768408 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-04-01 2018-06-30 0000768408 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cyan:CustomerNumber1Member 2018-04-01 2018-06-30 0000768408 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember cyan:CustomerNumber2Member 2018-04-01 2018-06-30 0000768408 cyan:BankOfTheWestFinanceMember 2018-04-01 2018-06-30 0000768408 cyan:BankOfTheWestFinanceMember cyan:CapitalLeaseAssesPayableIn36EqualMonthlyPaymentsMember 2018-04-01 2018-06-30 0000768408 cyan:The2015LoanAgreementMember 2018-04-01 2018-06-30 0000768408 cyan:The2015LoanAgreementMember us-gaap:PrimeRateMember 2018-04-01 2018-06-30 0000768408 cyan:AstaxanthinMember 2018-04-01 2018-06-30 0000768408 cyan:BulkAstaxanthinMember 2018-04-01 2018-06-30 0000768408 cyan:BulkProductsMember 2018-04-01 2018-06-30 0000768408 cyan:BulkSpirulinaMember 2018-04-01 2018-06-30 0000768408 us-gaap:DepositAccountMember 2018-04-01 2018-06-30 0000768408 cyan:PackagedAstaxanthinMember 2018-04-01 2018-06-30 0000768408 cyan:PackagedProductsMember 2018-04-01 2018-06-30 0000768408 cyan:PackagedSpirulinaMember 2018-04-01 2018-06-30 0000768408 cyan:SpirulinaMember 2018-04-01 2018-06-30 0000768408 us-gaap:EquipmentMember srt:MaximumMember 2018-04-01 2018-06-30 0000768408 us-gaap:EquipmentMember srt:MinimumMember 2018-04-01 2018-06-30 0000768408 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2018-04-01 2018-06-30 0000768408 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2018-04-01 2018-06-30 0000768408 us-gaap:LeaseholdImprovementsMember srt:MaximumMember 2018-04-01 2018-06-30 0000768408 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2018-04-01 2018-06-30 0000768408 us-gaap:DirectorMember 2018-04-01 2018-06-30 0000768408 cyan:Range01Member 2018-04-01 2018-06-30 0000768408 cyan:Range02Member 2018-04-01 2018-06-30 0000768408 cyan:Range03Member 2018-04-01 2018-06-30 0000768408 cyan:Range04Member 2018-04-01 2018-06-30 0000768408 us-gaap:RestrictedStockUnitsRSUMember cyan:EmployeesMember 2018-04-05 2018-04-05 0000768408 us-gaap:RestrictedStockUnitsRSUMember cyan:The2016PlanMember us-gaap:SubsequentEventMember 2018-07-01 2018-08-01 0000768408 cyan:TermLoanAgreementMaturingOnAugust142032Member 2012-08-14 0000768408 cyan:The2014DirectorsPlanMember 2014-08-28 0000768408 cyan:The2016PlanMember 2016-08-25 0000768408 cyan:The2016PlanMember srt:MaximumMember 2016-08-25 0000768408 us-gaap:RevolvingCreditFacilityMember cyan:FirstFoundationBankMember 2016-08-30 0000768408 2017-03-31 0000768408 2017-06-30 0000768408 cyan:EquipmentFinanceAgreementMember 2017-10-06 0000768408 2018-03-31 0000768408 us-gaap:RestrictedStockUnitsRSUMember 2018-03-31 0000768408 cyan:BankOfTheWestFinanceMember 2018-03-31 0000768408 cyan:TermLoanAgreementMaturingOnAugust142032Member 2018-03-31 0000768408 cyan:The2015LoanAgreementMember 2018-03-31 0000768408 us-gaap:EquipmentMember 2018-03-31 0000768408 us-gaap:FurnitureAndFixturesMember 2018-03-31 0000768408 us-gaap:LeaseholdImprovementsMember 2018-03-31 0000768408 2018-06-30 0000768408 us-gaap:EmployeeStockOptionMember 2018-06-30 0000768408 us-gaap:RestrictedStockUnitsRSUMember 2018-06-30 0000768408 us-gaap:RestrictedStockUnitsRSUMember cyan:The2016PlanMember 2018-06-30 0000768408 cyan:BankOfTheWestFinanceMember 2018-06-30 0000768408 cyan:BankOfTheWestFinanceMember cyan:CapitalLeaseAssesPayableIn36EqualMonthlyPaymentsMember 2018-06-30 0000768408 cyan:BankOfTheWestFinanceMember srt:MaximumMember 2018-06-30 0000768408 cyan:BankOfTheWestFinanceMember srt:MinimumMember 2018-06-30 0000768408 us-gaap:RevolvingCreditFacilityMember cyan:FirstFoundationBankMember 2018-06-30 0000768408 us-gaap:RevolvingCreditFacilityMember cyan:FirstFoundationBankMember us-gaap:PrimeRateMember 2018-06-30 0000768408 cyan:TermLoanAgreementMaturingOnAugust142032Member 2018-06-30 0000768408 cyan:The2015LoanAgreementMember 2018-06-30 0000768408 cyan:The2015LoanAgreementMember srt:MinimumMember 2018-06-30 0000768408 cyan:The2015LoanAgreementMember us-gaap:PrimeRateMember 2018-06-30 0000768408 cyan:The2004DirectorsPlanMember 2018-06-30 0000768408 cyan:The2005PlanMember 2018-06-30 0000768408 cyan:The2014DirectorsPlanMember 2018-06-30 0000768408 cyan:The2016PlanMember 2018-06-30 0000768408 us-gaap:EquipmentMember 2018-06-30 0000768408 us-gaap:FurnitureAndFixturesMember 2018-06-30 0000768408 us-gaap:LeaseholdImprovementsMember 2018-06-30 0000768408 us-gaap:DirectorMember 2018-06-30 0000768408 cyan:Range01Member 2018-06-30 0000768408 cyan:Range02Member 2018-06-30 0000768408 cyan:Range03Member 2018-06-30 0000768408 cyan:Range04Member 2018-06-30 0000768408 2018-08-07

EX-101.SCH 7 cyan-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Disclosure - Note 1 - Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 2 - Inventories link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 3 - Equipment and Leasehold Improvements, Net link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 4 - Line of Credit link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 5 - Accrued Expenses link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 6 - Long-term Debt link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 7 - Operating Leases link:calculationLink link:definitionLink link:presentationLink 012 - Document - Note 8 - Other Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 9 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 10 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 12 - Concentrations of Risk link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 1 - Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 2 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 3 - Equipment and Leasehold Improvements, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 5 - Accrued Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 6 - Long-term Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 7 - Operating Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 9 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 1 - Significant Accounting Policies - Revenue By Product (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 2 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 2 - Inventories - Components of Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 3 - Equipment and Leasehold Improvements, Net (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 3 - Equipment and Leasehold Improvements, Net - Estimated Useful Lives (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 3 - Equipment and Leasehold Improvements, Net - Components of Equipment and Leasehold Improvements (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 4 - Line of Credit (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 5 - Accrued Expenses - Components of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 6 - Long-term Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 6 - Long-term Debt - Summary of Long-term Debt (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 6 - Long-term Debt - Future Payments (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 7 - Operating Leases - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 9 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 9 - Share-based Compensation - Shares Authorized, Available for Future Grant and Outstanding Under Each Plan (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 9 - Share-based Compensation - Summary of Option Activity Under Stock Plans (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 9 - Share-based Compensation - Summary of Non-vested Options (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 9 - Share-based Compensation - Summary of the Weighted-average Characteristics of Outstanding Stock Options (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 9 - Share-based Compensation - Restricted Stock Units (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 10 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 12 - Concentrations of Risk (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 cyan-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cyan-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cyan-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Dividend Rate Note To Financial Statement Details Textual us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice Exercise Price (in dollars per share) Significant Accounting Policies Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Note 1 - Significant Accounting Policies Note 2 - Inventories us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Risk Free Rate Customer Number 3 [Member] Information pertaining to customer number 3 accounting for a percentage of accounts receivable. Note 3 - Equipment and Leasehold Improvements, Net Note 5 - Accrued Expenses Note 6 - Long-term Debt Note 7 - Operating Leases Note 9 - Share-based Compensation Note 11 - Earnings (Loss) Per Share Income Tax Disclosure [Text Block] Note 1 - Significant Accounting Policies - Revenue By Product (Details) Note 2 - Inventories - Components of Inventory (Details) Note 3 - Equipment and Leasehold Improvements, Net - Estimated Useful Lives (Details) Other assets us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Volatility Note 3 - Equipment and Leasehold Improvements, Net - Components of Equipment and Leasehold Improvements (Details) Share-based compensation expense us-gaap_LiabilitiesCurrent Total current liabilities Note 5 - Accrued Expenses - Components of Accrued Expenses (Details) Schedule of Maturities of Long-term Debt [Table Text Block] Note 6 - Long-term Debt - Summary of Long-term Debt (Details) Title of Individual [Axis] Note 6 - Long-term Debt - Future Payments (Details) Relationship to Entity [Domain] Note 7 - Operating Leases - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Expected Life (in years) (Year) Note 9 - Share-based Compensation - Shares Authorized, Available for Future Grant and Outstanding Under Each Plan (Details) Note 9 - Share-based Compensation - Summary of Option Activity Under Stock Plans (Details) Note 9 - Share-based Compensation - Summary of Non-vested Options (Details) Note 9 - Share-based Compensation - Summary of the Weighted-average Characteristics of Outstanding Stock Options (Details) RECONCILIATION OF CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD: Note 9 - Share-based Compensation - Summary of Valuation Assumptions Related to Options Granted (Details) Note 9 - Share-based Compensation - Restricted Stock Units (Details) Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 11 - Earnings (Loss) Per Share - Summary of Reconciliations Between the Numerator and the Denominator of the Basic and Diluted Earnings Per Share Computations (Details) OPERATING EXPENSES: Notes To Financial Statements Notes To Financial Statements [Abstract] Share-based Compensation, Stock Options, Activity [Table Text Block] Granted, weighted average grant price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested, weighted average grant price (in dollars per share) Forfeited, weighted average grant price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Nonvested restricted stock units at March 31, 2017, weighted average grant price (in dollars per share) Nonvested restricted stock units at March 31, 2018, weighted average grant price (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Outstanding (in shares) Nonvested restricted stock units at March 31, 2018 (in shares) Nonvested restricted stock units at June 30, 2018 (in shares) Schedule of Nonvested Share Activity [Table Text Block] Current maturities of long-term debt Less current maturities cyan_LongTermDebtAndCapitalLeaseObligationsCurrentAndNoncurrent Long-term Debt and Capital Lease Obligations, Current and Noncurrent Sum of the carrying values as of the balance sheet date of both current and noncurrent portions of long-term debt and capital lease obligations. Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested (in shares) Depreciation and amortization 2014 Directors Plan [Member] Represents the "2014 Directors Plan." The 2005 Plan [Member] Represents the "2005 Plan." Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] 2004 Directors Plan [Member] Represents the "2004 Directors Plan." us-gaap_AssetsCurrent Total current assets us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Exercisable, weighted average exercise price (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Exercisable, weighted average remaining contractual term (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Exercisable, aggregate intrinsic value Property, Plant, and Equipment, Estimated Useful Lives [Table Text Block] Tabular disclosure of the useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Exercisable (in shares) Line of credit Line of Credit, Current us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Outstanding, weighted average remaining contractual term (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Outstanding, aggregate intrinsic value Granted (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Vested (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue Forfeited (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Nonvested (in dollars per share) Nonvested (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Vested (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares Forfeited (in shares) us-gaap_InterestIncomeExpenseNonoperatingNet Interest expense, net Common stock of $0.02 par value, authorized 50,000,000 shares; 5,788,887 shares issued and outstanding at June 30, 2018 and 5,772,032 at March 31, 2018 us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Nonvested (in shares) Nonvested (in shares) Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Rent and utilities Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements and utilities, such as electrical power, heating oil, natural gas, and water. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Common stock, shares authorized (in shares) us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Forfeited, weighted average exercise price (in dollars per share) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Granted, weighted average exercise price (in dollars per share) us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Exercised, weighted average exercise price (in dollars per share) Capital Lease Asses Payable in 36 Equal Monthly Payments [Member] Represents information regarding to capital lease assets which are payable in 36 equal payments. Accrued expenses Total accrued expenses The 2016 Plan [Member] Represents the 2016 Cyanotech Equity Incentive Plan (the “2016 Plan”). Range [Domain] Maximum [Member] cyan_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedForIssuanceInConnectionWithPerformanceAwardsAndStockAwards Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized for Issuance in Connection with Performance Awards and Stock Awards The maximum number of shares (or other type of equity) originally approved to be issued in connection with performance awards and stock awards (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). Minimum [Member] Accounts payable Revolving Credit Facility [Member] Product and Service [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding (in shares) Outstanding (in shares) Product and Service [Domain] Range [Axis] Credit Facility [Axis] Credit Facility [Domain] Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding Other accrued expenses Preferred, issued shares (in shares) Long-term debt, less current maturities Total long-term debt, net of current maturities and unamortized debt issuance costs Amount of long-term debt and capital lease obligation net of issuance costs, due after one year or beyond the normal operating cycle, if longer. Wages, commissions, bonus and profit sharing Interest us-gaap_PolicyTextBlockAbstract Accounting Policies Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Preferred, authorized shares (in shares) Inventories, net Inventories, net us-gaap_PaymentsToAcquireProductiveAssets Investment in equipment and leasehold improvements Available (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Preferred stock, par value (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Customer [Axis] Authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Customer [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period SHARES USED IN CALCULATION OF NET (LOSS) INCOME PER SHARE: Income taxes Current liabilities: us-gaap_IncreaseDecreaseInCustomerDeposits Customer deposits us-gaap_Assets Total assets SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Plan Name [Axis] Estimated useful lives (Year) Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total CASH FLOWS FROM OPERATING ACTIVITIES: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Revenue Recognition, Policy [Policy Text Block] Statement [Line Items] Accounts receivable, allowance for doubtful accounts Accounts receivable, net of allowance for doubtful accounts of $27 at June 30, 2018 and $27 at March 31, 2018 Furniture and Fixtures [Member] Effect of dilutive securities on net income Additional paid-in capital Bank of the West Finance [Member] Finance agreements with Bank of the West. Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stockholders’ equity: Leasehold Improvements [Member] Equipment Finance Agreement [Member] A financing agreement that allows for the purchase of equipment by the reporting entity. Packaged Astaxanthin [Member] Refers to information regarding packaged Astaxanthin. Property, Plant and Equipment, Type [Axis] Bulk Products [Member] Refers to information regarding bulk products. Segment Reporting Disclosure [Text Block] Property, Plant and Equipment, Type [Domain] Packaged Products [Member] Refers to information regarding the packaged products. Deposit Account [Member] Equity Award [Domain] Bulk Spirulina [Member] Refers to information regarding bulk Spirulina. cyan_DebtAgreementMaximumBorrowingCapacity Debt Agreement, Maximum Borrowing Capacity Maximum borrowing capacity under a debt agreement on the amount that could be borrowed with a combination of, but not limited to, a line of credit and term loan. Bulk Astaxanthin [Member] Refers to information regarding bulk Astaxanthin. Packaged Spirulina [Member] Refers to information regarding packaged Spirulina. Current assets: us-gaap_CustomerDepositsCurrent Customer deposits us-gaap_RestrictedCashAndCashEquivalents Restricted cash Spirulina [Member] Refers to information regarding Spirulina. Award Type [Axis] Astaxanthin [Member] Refers to information regarding Astaxanthin. Net (loss) income NET (LOSS) INCOME Net income (loss) us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and restricted cash at beginning of period Cash at end of period ASSETS Restricted Stock Units (RSUs) [Member] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash and restricted cash First Foundation Bank [Member] Represents information about First Foundation Bank. us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities Commitments and contingencies us-gaap_OperatingIncomeLoss (Loss) income from operations us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized Employee Stock Option [Member] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash (used in) provided by operating activities Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] us-gaap_GrossProfit Gross Profit COST OF SALES Counterparty Name [Axis] Counterparty Name [Domain] us-gaap_DueToRelatedPartiesCurrentAndNoncurrent Due to Related Parties, Total Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation and amortization us-gaap_PropertyPlantAndEquipmentNet Equipment and leasehold improvements, net Equipment and leasehold improvements, net us-gaap_CapitalLeasedAssetsGross Capital Leased Assets, Gross, Total EX-101.PRE 11 cyan-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 a1.jpg begin 644 a1.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Jun. 30, 2018	Aug. 07, 2018
Document Information [Line Items]
Entity Registrant Name	Cyanotech Corp
Entity Central Index Key	0000768408
Trading Symbol	cyan
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		5,788,887
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018
Current assets:
Cash	$ 935	$ 1,329
Accounts receivable, net of allowance for doubtful accounts of $27 at June 30, 2018 and $27 at March 31, 2018	2,804	2,664
Inventories, net	9,487	9,034
Prepaid expenses and other current assets	593	590
Total current assets	13,819	13,617
Equipment and leasehold improvements, net	15,432	15,734
Restricted cash		65
Other assets	280	291
Total assets	29,531	29,707
Current liabilities:
Line of credit	1,250	500
Current maturities of long-term debt	660	655
Customer deposits	300	133
Accounts payable	3,735	3,527
Accrued expenses	1,000	892
Total current liabilities	6,945	5,707
Long-term debt, less current maturities	5,636	5,790
Other long-term liabilities	98	103
Total liabilities	12,679	11,600
Commitments and contingencies
Stockholders’ equity:
Preferred stock of $0.01 par value, authorized 10,000,000 shares; no shares issued and outstanding
Common stock of $0.02 par value, authorized 50,000,000 shares; 5,788,887 shares issued and outstanding at June 30, 2018 and 5,772,032 at March 31, 2018	116	115
Additional paid-in capital	32,070	32,051
Accumulated deficit	(15,334)	(14,059)
Total stockholders’ equity	16,852	18,107
Total liabilities and stockholders’ equity	$ 29,531	$ 29,707

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018
Accounts receivable, allowance for doubtful accounts	$ 27	$ 27
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred, authorized shares (in shares)	10,000,000	10,000,000
Preferred, issued shares (in shares)	0	0
Preferred outstanding, shares (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.02	$ 0.02
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	5,788,887	5,772,032
Common stock, shares outstanding (in shares)	5,788,887	5,772,032

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Revenue	$ 7,145	$ 8,809
COST OF SALES	5,309	5,206
Gross Profit	1,836	3,603
OPERATING EXPENSES:
General and administrative	1,372	1,352
Sales and marketing	1,423	1,489
Research and development	208	142
Total operating expenses	3,003	2,983
(Loss) income from operations	(1,167)	620
Interest expense, net	130	108
(Loss) income before income tax	(1,297)	512
INCOME TAX (BENEFIT) EXPENSE	(22)	11
NET (LOSS) INCOME	$ (1,275)	$ 501
NET (LOSS) INCOME PER SHARE:
Basic (in dollars per share)	$ (0.22)	$ 0.09
Diluted (in dollars per share)	$ (0.22)	$ 0.09
SHARES USED IN CALCULATION OF NET (LOSS) INCOME PER SHARE:
Basic (in shares)	5,785	5,685
Diluted (in shares)	5,785	5,719

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (1,275)	$ 501
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	475	479
Amortization of debt issue costs and other assets	19	15
Share-based compensation expense	34	31
Net (increase) decrease in assets:
Accounts receivable	(140)	(484)
Inventories	(453)	(9)
Prepaid expenses and other assets	(3)	138
Net increase (decrease) in liabilities:
Customer deposits	167	(40)
Accounts payable	208	(534)
Accrued expenses	108	130
Deferred rent and other liabilities	(5)	(17)
Net cash (used in) provided by operating activities	(865)	210
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in equipment and leasehold improvements	(173)	(56)
Net cash used in investing activities	(173)	(56)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net draws (payments) on line of credit	750	(111)
Principal payments on long-term debt	(141)	(130)
Payments on capitalized leases	(16)	(21)
Withholding on restricted stock unit vesting	(32)
Proceeds from stock options exercised	18
Net cash provided by (used in) financing activities	579	(262)
Net decrease in cash and restricted cash	(459)	(108)
Cash and restricted cash at beginning of period	1,394	1,407
Cash at end of period	935	1,299
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest	103	104
Income taxes
RECONCILIATION OF CASH AND RESTRICTED CASH AT BEGINNING OF PERIOD:
Cash	1,329	1,407
Restricted cash	65
Cash and restricted cash at beginning of period	$ 1,394	$ 1,407

XML 18 R6.htm IDEA: XBRL DOCUMENT

Note 1 - Significant Accounting Policies

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

1.	SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

-Q and Regulation S-

of the Securities and Exchange Commission (SEC). These interim condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to present fairly the Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations, and Condensed Consolidated Statements of Cash Flows for the periods presented in accordance with GAAP. Accordingly, they do

not

include all of the information and notes required by GAAP for complete financial statements. The results of operations for the interim periods are

not

necessarily indicative of the results to be expected for the full fiscal year. The Condensed Consolidated Balance Sheet as of

March

31,

2018

was derived from the audited consolidated financial statements. These condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited consolidated financial statements for the year ended

March

31,

2018,

contained in the Company’s annual report on Form

-K as filed with the SEC on

June

15,

2018.

Liquidity

As of

June 30, 2018,

the Company had cash of

$0.9

million and working capital of

$6.9

million compared to

$1.3

million and

$7.9

million, respectively, at

March 31, 2018.

August 30, 2016,

the Credit Agreement, which the Company and First Foundation Bank (the Bank) entered into on

June 3, 2016,

became effective. The Credit Agreement allows the Company to borrow up to

$2.0

million on a revolving basis. At

June 30, 2018,

the Company had borrowed

$1.25

million and had

$0.75

million available on the line. The line of credit was renewed on

August 30, 2017

and will expire on

August 30, 2018.

The Company intends to renew or replace it with another line of credit on or before the expiration date.

As of

June 30, 2018,

the Company had

$6.2

million of term loans payable to the Bank that require the payment of principal and interest monthly through

August 2032.

Pursuant to the term loans, the Company is subject to annual financial covenants, customary affirmative and negative covenants and certain subjective acceleration clauses. As of

March 31, 2018,

the Company was in compliance with these financial covenants.

2019

operating plan and related cash flow projections and the Company’s projected consolidated financial position as of

March 31, 2019,

cash flows expected to be generated by operating activities and available financing are expected to be sufficient to fund the Company’s operations for at least the next

twelve

months, and the Company’s current ratio is expected to be in compliance with the annual term loan covenant requirement as of

March 31, 2019.

However,

assurances can be provided that the Company will achieve its operating plan and cash flow objectives for the next fiscal year or its projected consolidated financial position as of

March 31, 2019.

Such estimates are subject to change based on future results and such change could cause future results to vary significantly from expected results.

Revenue Recognition

The Company records revenue based on the

five

-step model which includes: (

) identifying the contract with the customer; (

) identifying the performance obligations in the contract; (

) determining the transaction price; (

) allocating the transaction price to the performance obligations; and (

) recognizing revenue when the performance obligations are satisfied. Substantially all of the Company’s revenue is generated by fulfilling orders for the purchase of our micro algal nutritional supplements to retailers, wholesalers, or direct to consumers via online channels, with each order considered to be a distinct performance obligation. These orders

may

be formal purchase orders, verbal phone orders, e-mail orders or orders received online. Shipping and handling activities for which the Company is responsible under the terms and conditions of the order are

not

accounted for as performance obligations but as fulfillment costs. These activities are required to fulfill the Company’s promise to transfer the goods and are expensed when revenue is recognized. The impact of this policy election is insignificant as it aligns with our current practice.

days from the invoice date, which occurs on the date of transfer of control of the products to the customer.

one

of our distribution centers by the customer.

Customer contract liabilities consist of customer deposits received in advance of fulfilling an order and are shown separately on the consolidated balance sheets. During the

three

-month periods ended

June 30, 2018,

and

June 30, 2017,

the Company recognized

$112,000

and

$45,000,

respectively of revenue from deposits that were included in contract liabilities as of

March 31, 2018

and

March 31, 2017,

respectively. The Company’s contracts have a duration of

one

year or less and therefore, the Company has elected the practical expedient of

not

disclosing revenues allocated to partially unsatisfied performance obligations.

The following table represents revenue disaggregated

by product in the

three

months ended

June 30, 2018

and

June 30, 2017 (

in thousands):

	Three months ended June 30, 2018
	Astaxanthin		Spirulina		Total
Packaged products	$	5,095	$	1,068	$	6,163
Bulk products		263		719		982
Total	$	5,358	$	1,787	$	7,145

	Three months ended June 30, 2017
	Astaxanthin		Spirulina		Total
Packaged products	$	5,505	$	1,927	$	7,432
Bulk products		221		1,156		1,377
Total	$	5,726	$	3,083	$	8,809

Recently Adopted Accounting Pronouncements

May 2017,

the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")

2017

09,

Compensation-Stock Compensation (Topic

718

) Scope of Modification Accounting

("ASU

No.

2017

09"

)

ASU

No.

2017

will clarify and reduce both (i) diversity in practice and (ii) cost and complexity when applying the guidance in Topic

718,

to a change to the terms and conditions of a share-based payment award. This guidance became effective for fiscal years beginning after

December 15, 2017

and interim periods within those fiscal years. The amendments in this ASU are applied prospectively to awards modified on or after the adoption date. The Company adopted this standard as of

April 1, 2018

with

impact on its consolidated financial statements.

November 2016,

the FASB issued ASU

2016

18,

“

Statement of Cash Flows (Topic

230

): Restricted Cash”

(“ASU

No.

2016

18”

)

This update addresses the fact that diversity exists in the classification and presentation of changes in restricted cash on the statement of cash flows under Topic

230,

Statement of Cash Flows

. ASU

No.

2016

became effective for public companies for the fiscal years beginning after

December 15, 2017,

and interim periods within those fiscal years. The Company adopted this standard as of

April 1, 2018

by using the retrospective method, which required reclassification of restricted cash in the accompanying consolidated statement of cash flows as of the beginning of the period for the

three

months ended

June 30, 2018.

August 2016,

FASB issued ASU

2016

15,

“

Statement of Cash Flows (Topic

230

)

Classification of Certain Cash Receipts and Cash Payments”

(“ASU

No.

2016

15”

). This ASU clarifies and provides specific guidance on

eight

cash flow classification issues that are

not

currently addressed by current GAAP and thereby reduces the current diversity in practice. ASU

No.

2016

is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after

December 15, 2017.

The Company adopted this standard as of

April 1, 2018

with

impact on its consolidated financial statements and related disclosures.

May 2014,

the FASB issued their converged standard on revenue recognition, Accounting Standards Update

No.

2014

09,

“

Revenue from Contracts with Customers (Topic

606

)”

("ASU

No.

2014

09"

), updated in

December 2016

with the release of ASU

2016

20.

This standard outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods and services in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. In

August 2015,

the FASB issued ASU

2015

“

Revenue from Contracts with Customers (Topic

606

Deferral of the Effective Date,

" which deferred the effective date of ASU

No.

2014

to annual reporting periods beginning after

December 15, 2017.

April 1, 2018

for contracts that were

not

completed before the adoption date, using the modified retrospective method. The Company has evaluated the effect of the standard and concluded it is

not

material to the timing or amount of revenues or expenses recognized in the Company’s historical consolidated financial statements. As a result, the Company has concluded that the application of the standard does

not

have a material effect that requires a retrospective adjustment to any previously reported amounts in the Company’s historical consolidated financial statements for reporting disclosure purposes.

Recently Issued Accounting Pronouncements

July 2018,

the FASB issued ASU

2018

“

Codification Improvements to Topic

842,

Leases

” (“ASU

No.

2018

02”

). This ASU affects narrow aspects of the guidance issued in the amendments in ASU

No.

2016

including those regarding residual value guarantees, rate implicit in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases under Topic

840,

transition guidance for modifications to leases previously classified as direct financing or sales-type leases under Topic

840,

transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions. The Company is currently evaluating the impact this ASU will have on its implementation of ASU

No.

2016

02.

June 2018,

the FASB issued ASU

2018

“

Compensation - Stock Compensation (Topic

718

)

”

(“ASU

No.

2018

07”

): Improvements to Nonemployee Share-Based Payment Accounting. This ASU expands the scope of Topic

718

to include share-based payment transactions for acquiring goods and services from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU

No.

2018

is effective for fiscal years beginning after

December 15, 2018,

including interim periods within that fiscal year. Early adoption is permitted but

earlier than an entity’s adoption date of Topic

606.

The Company is currently evaluating the impact this new guidance will have on its financial statements and related disclosures.

February 2016,

the FASB issued ASU

2016

02,

“

Leases (Topic

842

)”

(

“

ASU

No.

2016

02”

). The principle objective of ASU

No.

2016

is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet. ASU

No.

2016

continues to retain a distinction between finance and operating leases but requires lessees to recognize a right-of-use asset representing its right to use the underlying asset for the lease term and a corresponding lease liability on the balance sheet for all leases with terms greater than

twelve

months. ASU

No.

2016

is effective for fiscal years and interim periods beginning after

December 15, 2018.

Early adoption of ASU

No.

2016

is permitted. Entities are required to apply the amendments at the beginning of the earliest period presented using a modified retrospective approach. This guidance is applicable to the Company’s fiscal year beginning

April 1, 2019.

July 2018,

the FASB issued ASU

No.

2018

11,

Leases (Topic

842

): Targeted Improvements

," which provides an additional transition method that permits changes to be applied by means of a cumulative-effect adjustment recorded in retained earnings as of the beginning of the fiscal year of adoption. The Company has started the assessment process by evaluating the population of leases under the revised definition of what qualifies as a leased asset, and expects to have the assessment completed by

March 2019.

The Company is the lessee under various agreements for facilities and equipment that are currently accounted for as operating and capital leases. The Company expects this guidance will have a material impact on its consolidated balance sheets due to the recognition of lease rights and obligations as assets and liabilities, respectively. The Company does

not

expect this guidance to have a material effect on its consolidated results of operations and cash flows.

XML 19 R7.htm IDEA: XBRL DOCUMENT

Note 2 - Inventories

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Inventory Disclosure [Text Block]

2.	INVENTORIES

Inventories are stated at the lower of cost or net realizable value. Cost is determined by the

first

-in,

first

-out method. Inventories consist of the following:

	June 30, 201 8		March 31, 201 8
	(in thousands)
Raw materials	$	371	$	410
Work in process		3,301		2,602
Finished goods		5,663		5,878
Supplies		152		144
Inventories, net	$	9,487	$	9,034

$250,000

were charged to cost of sales for the quarter ended

June 30, 2018.

There were

abnormal production costs for the quarter ended

June 30, 2017.

Non-inventoriable fixed costs related to spirulina production of

$125,000

were charged to cost of sales for the quarter ended

June

30,

2018.

Non-inventoriable fixed costs related to spirulina production of

$9,000

were charged to cost of sales for the quarter ended

June

30,

2017.

XML 20 R8.htm IDEA: XBRL DOCUMENT

Note 3 - Equipment and Leasehold Improvements, Net

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

3.	EQUIPMENT AND LEASEHOLD IMPROVEMENTS, NET

	Years
Equipment		3	to	10
Furniture and fixtures		3	to	7
Leasehold improvements		10	to	25

Equipment and leasehold improvements consist of the following:

	June 30, 201 8			March 31, 201 8
	(in thousands)
Equipment	$	18,114		$	17,935
Leasehold improvements		14,287			14,248
Furniture and fixtures		348			348
		32,749			32,531
Less accumulated depreciation and amortization		(17,821	)		(17,346	)
Construction-in-progress		504			549
Equipment and leasehold improvements, net	$	15,432		$	15,734

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of such assets

may

not

be recoverable. Recoverability of these assets is measured by a comparison of the carrying amount to forecasted undiscounted future cash flows expected to be generated by the asset. If the carrying amount exceeds its estimated future cash flows, then an impairment charge is recognized to the extent that the carrying amount exceeds the asset’s fair value. Management has determined

asset impairment existed as of

June

30,

2018

and

March 31, 2018,

respectively.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Note 4 - Line of Credit

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Short-term Debt [Text Block]

4.	LINE OF CREDIT

August 30, 2016,

the Revolving Credit Agreement (the “Credit Agreement”), which the Company and First Foundation Bank (“the Bank”) entered into on

June 3, 2016,

became effective after the Company and the Bank received the necessary approvals from the State of Hawaii to secure the lien on the Company’s leasehold property in Kona, Hawaii. The Credit Agreement allows the Company to borrow up to

$2,000,000

on a revolving basis. Borrowings under the Credit Agreement bear interest at the Wall Street Journal prime rate (

5.00%

June 30, 2018) +

2%,

floating. The Credit Agreement includes various covenants as defined in the Credit Agreement. The Credit Agreement also contains standard acceleration provisions in the event of a default by the Company. At

June 30, 2018,

the Company had borrowed

$1,250,000

under the Credit Agreement and had

$750,000

available on the line. The line of credit will be subject to renewal upon expiration on

August 30, 2018.

XML 22 R10.htm IDEA: XBRL DOCUMENT

Note 5 - Accrued Expenses

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

5.	ACCRUED EXPENSES

Accrued expenses consist of the following:

	June 30, 201 8		March 31, 201 8
	(in thousands)
Wages, commissions, bonus and profit sharing	$	807	$	707
Rent and utilities		69		69
Other accrued expenses		124		116
Total accrued expenses	$	1,000	$	892

XML 23 R11.htm IDEA: XBRL DOCUMENT

Note 6 - Long-term Debt

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Long-term Debt [Text Block]

6.	LONG-TERM DEBT

Long-term debt consists of the following:

	June 30, 201 8			March 31, 201 8
	(in thousands)
Long-term debt	$	6,520		$	6,678
Less current maturities		(660	)		(655	)
Long-term debt, excluding current maturities		5,860			6,023
Less unamortized debt issuance costs		(224	)		(233	)
Total long-term debt, net of current maturities and unamortized debt issuance costs	$	5,636		$	5,790

Term Loans

The Company executed a loan agreement with a lender providing for

$2,500,000

in aggregate credit facilities (the

“2015

Loan”) secured by substantially all the Company’s assets, pursuant to a Term Loan Agreement dated

July

30,

2015

(the

“2015

Loan Agreement”). The

2015

Loan Agreement is evidenced by a promissory note in the amount of

$2,500,000,

the repayment of which is partially guaranteed under the provisions of a United States Department of Agriculture (“USDA”) Rural Development Guarantee program. The proceeds of the

2015

Loan were used to pay off a

$500,000

short term note payable that matured on

September 18, 2015,

and to acquire new processing equipment and leasehold improvements at the Company’s Kona, Hawaii facility.

The provisions of the

2015

Loan Agreement require the payment of principal and interest until its maturity on

September

2022,

the obligation fully amortizes over

seven

(

) years. Interest on the

2015

Loan accrues on the outstanding principal balance at an annual variable rate equal to the published Wall Street Journal prime rate (

5.00%

June

30,

2018

) plus

2.0%

and is adjustable on the

first

day of each calendar quarter and fixed for that quarter. At

time shall the annual interest rate be less than

6.00%.

The

2015

Loan has a prepayment penalty of

for any prepayment made prior to the

first

anniversary of the date of the

2015

Loan Agreement, which penalty is reduced by

each year thereafter until the

fifth

anniversary of such date, after which there is

prepayment penalty. The balance under the

2015

Loan was

$1,644,000

and

$1,726,000

June 30, 2018

and

March

31,

2018,

respectively.

The

2015

Loan includes a

one

-time origination and guaranty fee totaling

$113,900

and an annual renewal fee payable in the amount of

0.50%

of the USDA guaranteed portion of the outstanding principal balance as of

December

of each year, beginning

December

31,

2015.

The USDA has guaranteed

80%

of all amounts owing under the

2015

Loan. The Company is subject to financial covenants and customary affirmative and negative covenants.

The Company executed a loan agreement with a lender providing for

$5,500,000

in aggregate credit facilities (the “Loan”) secured by substantially all the Company’s assets, including a mortgage on the Company's interest in its lease at the National Energy Laboratory of Hawaii Authority, pursuant to a Term Loan Agreement dated

August

14,

2012

(the “Loan Agreement”). The Loan Agreement is evidenced by promissory notes in the amounts of

$2,250,000

and

$3,250,000,

the repayment of which is partially guaranteed under the provisions of a USDA Rural Development Guarantee. The proceeds of the Loan have been used to acquire new processing equipment and leasehold improvements at the Company’s Kona, Hawaii facility.

The provisions of the Loan required the payment of interest only for the

first

months of the term; thereafter, and until its maturity on

August

14,

2032,

the obligation fully amortizes over

nineteen

(

) years. Interest on the Loan accrues on the outstanding principal balance at an annual variable rate equal to the published Wall Street Journal prime rate (

5.00%

June

30,

2018

) plus

1.0%

and is adjustable on the

first

day of each calendar quarter and fixed for that quarter. At

time shall the annual interest rate be less than

5.50%.

The balance under this Loan was

$4,596,000

and

$4,648,000

June 30, 2018

and

March

31,

2018,

respectively.

The Loan includes a

one

-time origination and guaranty fees totaling

$214,500

and an annual renewal fee payable in the amount of

0.25%

of the USDA guaranteed portion of the outstanding principal balance as of

December

of each year, beginning

December

31,

2012.

The USDA has guaranteed

80%

of all amounts owing under the Loan. The Company is subject to financial covenants and customary affirmative and negative covenants.

October 6, 2017,

the Company entered into an Equipment Finance Agreement (the “Equipment Agreement”) with a lender, which provides up to

$175,000

of financing for equipment. The interest rate on this loan is

4.75%.

The provisions of the Equipment Agreement require the payment of principal and interest until its maturity on

October

31,

2022,

the obligation fully amortizes over

five

(

) years. The balance under this loan was

$149,000

and

$156,000

June 30, 2018

and

March 31, 2018,

respectively.

Capital Leases

The Company has

three

capital leases providing for

$278,000

in equipment, secured by the equipment financed. The capital leases mature at various dates between

May 2019

and

March 2021

and are payable in

equal monthly payments, except for

one

which is payable in

equal monthly payments. The interest rates under these capital leases range from

4.18%

12.90%.

The aggregate balance under these leases was

$131,000

and

$148,000

June

30,

2018

and

March 31, 2018,

respectively.

Future principal payments under the term loan and capital lease agreements as of

June

30,

2018

are as follows:

Payments Due	(in thousands)
Next 12 Months	$	660
Year 2		684
Year 3		685
Year 4		716
Year 5		398
Thereafter		3,377
Total principal payments	$	6,520

XML 24 R12.htm IDEA: XBRL DOCUMENT

Note 7 - Operating Leases

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Leases of Lessee Disclosure [Text Block]

7.	OPERATING LEASES

The Company leases facilities, equipment and land under operating leases expiring through

2035.

The land lease provides for contingent rentals in excess of minimum rental commitments based on a percentage of the Company’s sales. Management has accrued for the estimated contingent rent as of

June

30,

2018.

Future minimum lease payments under all non-cancelable operating leases at

June

30,

2018

are as follows:

Payments Due	(in thousands)
Next 12 Months	$	628
Year 2		611
Year 3		537
Year 4		533
Year 5		397
Thereafter		3,741
Total minimum lease payments	$	6,447

XML 25 R13.htm IDEA: XBRL DOCUMENT

Note 8 - Other Commitments and Contingencies

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

8.	OTHER COMMITMENTS AND CONTINGENCIES

From time to time, the Company

may

be involved in litigation and investigations relating to claims and matters arising out of its operations in the normal course of business. The Company believes that it currently is

not

a party to any legal proceedings or claims which, individually or in aggregate, would have a material effect on its consolidated financial position, results of operations or cash flows.

XML 26 R14.htm IDEA: XBRL DOCUMENT

Note 9 - Share-based Compensation

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

9.	SHARE-BASED COMPENSATION

liability-classified awards. Equity-classified awards, including grants of employee stock options, are measured at the grant-date fair value of the award and are

not

subsequently remeasured unless an award is modified. The cost of equity-classified awards is recognized in the statement of operations over the period during which an employee is required to provide the service in exchange for the award, or the vesting period. All of the Company’s stock options are service-based awards, and because the Company’s stock options are “plain vanilla,” as defined by the U.S. Securities and Exchange Commission in Staff Accounting Bulletin

No.

107,

they are reflected only in equity and compensation expense accounts.

As of

June

30,

2018,

the Company had

two

equity-based compensation plans: the

2016

Equity Incentive Plan (the

2016

Plan) and the

2014

Independent Director Stock Option and Restricted Stock Grant Plan (the

“2014

Directors Plan”). The Company has also issued stock options, which remain outstanding as of

June 30, 2018,

under

two

equity-based compensation plans which have expired according to their terms: the

2005

Stock Option Plan (the

“2005

Plan”) and the

2004

Independent Director Stock Option and Stock Grant Plan (the

“2004

Directors Plan”). These plans allowed the Company to award stock options and shares of restricted common stock to eligible employees, certain outside consultants and independent directors.

additional awards will be issued under the

2005

Plan or the

2004

Directors Plan.

August 25, 2016,

the Company’s shareholders approved the

2016

Plan as a successor to the

2005

Plan, authorizing the Board of Directors to provide incentive to the Company’s officers, employees and certain independent consultants through equity based compensation in the form of stock options, restricted stock, restricted stock units, stock appreciation rights and other stock based awards (together, “Stock Awards”) and performance shares and performance units (together “Performance Awards”). Awards under the

2016

Plan are limited to the authorized amount of

1,300,000

shares, up to

600,000

of which are available for issuance in connection with Performance Awards and Stock Awards. As of

June 30, 2018,

there were

1,131,483

shares available for grant under the

2016

Plan.

August 28, 2014,

the Company’s shareholders approved the

2014

Directors Plan authorizing the Board of Directors to provide incentive to the Company’s independent directors through equity based compensation in the form of stock options and restricted stock. Awards under the

2014

Directors Plan are limited to the authorized amount of

350,000

shares. As of

June 30, 2018,

there were

231,623

shares available for grant under the

2014

Directors Plan.

The following table presents shares authorized, available for future grant and outstanding under each of the Company’s plans:

	As of June 30, 201 8
	Authorized		Available		Outstanding

2016 Plan		1,300,000		1,131,483		152,514
2014 Directors Plan		350,000		231,623		12,000
2005 Plan		—		—		437,400
2004 Directors Plan		—		—		12,000
Total		1,650,000		1,363,106		613,914

Stock Options

All stock option grants made under the equity-based compensation plans were issued at exercise prices

less than the Company’s closing stock price on the date of grant. Options under the

2005

Plan and

2014

Directors Plan were determined by the Board of Directors or the Compensation Committee of the Board of Directors in accordance with the provisions of the respective plans. The terms of each option grant include vesting, exercise, and other conditions are set forth in a Stock Option Agreement evidencing each grant.

option can have a life in excess of

ten

(

) years. The Company records compensation expense for employee stock options based on the estimated fair value of the options on the date of grant using the Black-Scholes option-pricing model. The model requires various assumptions, including a risk-free interest rate, the expected term of the options, the expected stock price volatility over the expected term of the options, and the expected dividend yield. Compensation expense for employee stock options is recognized ratably over the vesting term. Compensation expense recognized for options issued under all Plans was

$18,000

and

$15,000

for the

three

months ended

June

30,

2018

and

2017,

respectively. All stock-based compensation has been classified as general and administrative expense in the condensed consolidated statement of operations.

A summary of option activity under the Company’s stock plans for the

three

months ended

June

30,

2018

is presented below:

Option Activity	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at March 31, 2018		589,400		$	4.06		4.9	$	675,300
Granted		—			—
Exercised		(6,000	)	$	2.85
Forfeited		(2,000	)	$	5.61
Outstanding at June 30, 2018		581,400		$	4.07		4.7	$	158,724
Exercisable at June 30, 2018		461,400		$	4.21		3.6	$	114,324

$3.90

for such day.

A summary of the Company’s non-vested options for the

three

months ended

June

30,

2018

is presented below:

Nonvested Options	Shares		Weighted Average Grant-Date Fair Value
Nonvested at March 31, 2018		120,000	$	1.81
Granted		—		—
Vested		—		—
Forfeited		—		—
Nonvested at June 30, 2018		120,000	$	1.81

The following table summarizes the weighted average characteristics of outstanding stock options as of

June

30,

2018:

			Outstanding Options						Exercisable Options
Range of Exercise Prices			Number of Shares		Remaining Life (Years)		Weighted Average Price		Number of Shares		Weighted Average Price
$1.60	-	$3.70		166,800		5.1	$	3.06		91,800	$	2.82
$3.71	-	$4.42		239,100		4.5		3.83		194,100		3.83
$4.43	-	$5.40		95,000		4.9		5.00		95,000		5.00
$5.41	-	$7.08		80,500		4.4		5.77		80,500		5.77
Total stock options				581,400		4.7	$	4.07		461,400	$	4.21

The range of fair value assumptions related to options granted during the year ended

March

31,

2018

were as follows:

	201 8
Exercise Price	$	3.83
Volatility		51.91	%
Risk Free Rate		2.50	%
Vesting Period (years)		3.0
Forfeiture Rate		0.00	%
Expected Life (in years)		6.00
Dividend Rate		0	%

As of

June

30,

2018,

total unrecognized stock-based compensation expense related to all unvested stock options was

$163,000,

which is expected to be expensed over a weighted average period of

2.0

years.

Restricted Stock Units (“RSUs”)

RSUs are service-based awards granted to eligible employees under the

2016

Plan. Compensation expense recognized for RSUs issued under the

2016

Plan was

$16,000

and

$16,000

for the

three

months ended

June 30, 2018

and

2017,

respectively.

April 5, 2018,

1,474

RSUs were awarded to employees of the Company. This award is valued at

$5.25

per share, the closing market price of Cyanotech common stock on the grant date, and vests over a period of

two

years.

The following table summarizes information related to awarded RSUs:

Nonvested Restricted Stock Units	Shares			Weighted Average Grant Price
Nonvested restricted stock units at March 31, 2018		39,675		$	3.89
Granted		1,474			5.25
Vested		(7,670	)		3.92
Forfeited		(965	)		4.29
Nonvested restricted stock units at June 30, 2018		32,514		$	3.93

As of

June

30,

2018,

total unrecognized stock-based compensation expense related to unvested restricted stock units was

$110,000,

which is expected to be expensed over a weighted average period of

1.8

years.

Subsequent to

June 30, 2018,

22,449

restricted stock units were granted from the

2016

Plan to employees and officers of the Company.

XML 27 R15.htm IDEA: XBRL DOCUMENT

Note 10 - Income Taxes

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Income Tax Disclosure [Text Block]

10.	INCOME TAXES

December 22, 2017

H.R.

originally known as the Tax Cuts and Jobs Act, (the “Tax Act”) was enacted. Among the significant changes to the U.S. Internal Revenue Code, the Tax Act lowers the U.S. federal corporate income tax rate (“Federal Tax Rate”) from

34%

21%

effective

January 1, 2018.

The Company will compute its income tax expense for the

March 31, 2019

fiscal year using a Federal Tax Rate of

21%.

The

21%

Federal Tax Rate will apply to fiscal years ending

March 31, 2019

and each year thereafter. The Company has completed the accounting for the income tax effects of the Tax Act as of

March 31, 2018

and has determined that the amount identified as provisional in the quarter ended

December 31, 2018

was a materially correct amount. As a result,

measurement period adjustments have been recorded.

$22,000

) and income tax expense of

$11,000

for the

three

months ended

June 30, 2018

and

2017,

respectively. Our effective tax rate was

1.7%

and

2.1%

for the quarters ended

June 30, 2018

and

June 30, 2017,

respectively. The effective tax rate for the

three

months ended

June 30, 2018

differs from the statutory rate of

21%

as a result of state taxes (net of federal benefit) and the net change in valuation allowance against the net deferred tax asset the Company believes is

not

more likely than

not

to be realized.

The Company is subject to taxation in the United States and

six

state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities. As part of these reviews, a taxing authority

may

disagree with respect to the tax positions taken by management (“uncertain tax positions”) and therefore

may

require the Company to pay additional taxes. Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events.

As of

June

30,

2018,

there was

liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its consolidated condensed statements of operations, which is consistent with the recognition of these items in prior reporting periods.

With few exceptions, the Company is

longer subject to U.S. federal, state, local, and non-U.S. income tax examination by tax authorities for tax years before

2013.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Note 11 - Earnings (Loss) Per Share

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]

11.	EARNINGS (LOSS) PER SHARE

Reconciliations between the numerator and the denominator of the basic and diluted earnings (loss) per share computations for the

three

months ended

June

30,

2018

and

2017

are as follows:

	Three Months Ended June 30, 201 8
	Net Loss (Numerator)			Shares (Denominator)		Per Share Amount
	(in thousands)
Basic and diluted loss per share	$	(1,275	)		5,785	$	(0.22	)

	Three Months Ended June 30, 201 7
	Net Income (Numerator)		Shares (Denominator)		Per Share Amount
	(in thousands)
Basic income per share	$	501		5,685	$	0.09
Effect of dilutive securities-Common stock options		—		34		—
Diluted income per share	$	501		5,719	$	0.09

Basic and diluted loss per share are the same in periods of a net loss, because common share equivalents are anti-dilutive when a net loss is recorded. Diluted earnings per share does

not

include the impact of common stock options totaling

120,000

and

for the

three

months ended

June

30,

2018

and

2017,

respectively, as the effect of their inclusion would be anti-dilutive. Restricted stock units become dilutive within the period granted and remain dilutive until the units vest and are issued as common stock. Diluted earnings per share does

not

include the impact of restricted stock units totaling

1,206

and

27,344

for the

three

months ended

June 30, 2018

and

2017,

as the effect of their inclusion would be anti-dilutive.

XML 29 R17.htm IDEA: XBRL DOCUMENT

Note 12 - Concentrations of Risk

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

12.	CONCENTRATIONS OF RISK

Concentration of Accounts Receivable and Revenues

June 30, 2018,

79%

of the Company’s accounts receivable was comprised of

two

customer balances of

42%

and

37%,

respectively. At

March 31, 2018,

77%

of the Company’s accounts receivable was comprised of

three

customer balances of

49%,

17%

and

11%,

respectively. There were

two

customers with sales representing

31%

and

27%

of our total net sales for the

three

months ended

June

30,

2018.

There were

two

customers with sales representing

32%

and

13%

of our total net sales for the

three

months ended

June

30,

2017.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Note 13 - Related Party Transactions and Balances

3 Months Ended

Jun. 30, 2018

Notes to Financial Statements

13.	RELATED PARTY TRANSACTIONS AND BALANCES

During the

three

months ended

June 30, 2018,

the Company entered into a consulting agreement with an effective date of

May 5, 2018

with a vendor that employs

one

of our independent directors. The Company’s independent director is

not

named in or involved in the performance of the consulting agreement. The contract amount is

$120,000.

$46,000

of the contract amount is reflected in general and administrative expense as of

June 30, 2018

and

payments have been made against the contract during the

three

months ended

June 30, 2018.

XML 31 R19.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Liquidity and Debt Covenant Compliance [Policy Text Block]

Liquidity

As of

June 30, 2018,

the Company had cash of

$0.9

million and working capital of

$6.9

million compared to

$1.3

million and

$7.9

million, respectively, at

March 31, 2018.

August 30, 2016,

the Credit Agreement, which the Company and First Foundation Bank (the Bank) entered into on

June 3, 2016,

became effective. The Credit Agreement allows the Company to borrow up to

$2.0

million on a revolving basis. At

June 30, 2018,

the Company had borrowed

$1.25

million and had

$0.75

million available on the line. The line of credit was renewed on

August 30, 2017

and will expire on

August 30, 2018.

The Company intends to renew or replace it with another line of credit on or before the expiration date.

As of

June 30, 2018,

the Company had

$6.2

million of term loans payable to the Bank that require the payment of principal and interest monthly through

August 2032.

Pursuant to the term loans, the Company is subject to annual financial covenants, customary affirmative and negative covenants and certain subjective acceleration clauses. As of

March 31, 2018,

the Company was in compliance with these financial covenants.

2019

operating plan and related cash flow projections and the Company’s projected consolidated financial position as of

March 31, 2019,

cash flows expected to be generated by operating activities and available financing are expected to be sufficient to fund the Company’s operations for at least the next

twelve

months, and the Company’s current ratio is expected to be in compliance with the annual term loan covenant requirement as of

March 31, 2019.

However,

assurances can be provided that the Company will achieve its operating plan and cash flow objectives for the next fiscal year or its projected consolidated financial position as of

March 31, 2019.

Such estimates are subject to change based on future results and such change could cause future results to vary significantly from expected results.

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

The Company records revenue based on the

five

-step model which includes: (

) identifying the contract with the customer; (

) identifying the performance obligations in the contract; (

) determining the transaction price; (

) allocating the transaction price to the performance obligations; and (

may

not

days from the invoice date, which occurs on the date of transfer of control of the products to the customer.

one

of our distribution centers by the customer.

Customer contract liabilities consist of customer deposits received in advance of fulfilling an order and are shown separately on the consolidated balance sheets. During the

three

-month periods ended

June 30, 2018,

and

June 30, 2017,

the Company recognized

$112,000

and

$45,000,

respectively of revenue from deposits that were included in contract liabilities as of

March 31, 2018

and

March 31, 2017,

respectively. The Company’s contracts have a duration of

one

year or less and therefore, the Company has elected the practical expedient of

not

disclosing revenues allocated to partially unsatisfied performance obligations.

The following table represents revenue disaggregated

by product in the

three

months ended

June 30, 2018

and

June 30, 2017 (

in thousands):

	Three months ended June 30, 2018
	Astaxanthin		Spirulina		Total
Packaged products	$	5,095	$	1,068	$	6,163
Bulk products		263		719		982
Total	$	5,358	$	1,787	$	7,145

	Three months ended June 30, 2017
	Astaxanthin		Spirulina		Total
Packaged products	$	5,505	$	1,927	$	7,432
Bulk products		221		1,156		1,377
Total	$	5,726	$	3,083	$	8,809

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Pronouncements

May 2017,

the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")

2017

09,

Compensation-Stock Compensation (Topic

718

) Scope of Modification Accounting

("ASU

No.

2017

09"

)

ASU

No.

2017

will clarify and reduce both (i) diversity in practice and (ii) cost and complexity when applying the guidance in Topic

718,

to a change to the terms and conditions of a share-based payment award. This guidance became effective for fiscal years beginning after

December 15, 2017

and interim periods within those fiscal years. The amendments in this ASU are applied prospectively to awards modified on or after the adoption date. The Company adopted this standard as of

April 1, 2018

with

impact on its consolidated financial statements.

November 2016,

the FASB issued ASU

2016

18,

“

Statement of Cash Flows (Topic

230

): Restricted Cash”

(“ASU

No.

2016

18”

)

This update addresses the fact that diversity exists in the classification and presentation of changes in restricted cash on the statement of cash flows under Topic

230,

Statement of Cash Flows

. ASU

No.

2016

became effective for public companies for the fiscal years beginning after

December 15, 2017,

and interim periods within those fiscal years. The Company adopted this standard as of

April 1, 2018

by using the retrospective method, which required reclassification of restricted cash in the accompanying consolidated statement of cash flows as of the beginning of the period for the

three

months ended

June 30, 2018.

August 2016,

FASB issued ASU

2016

15,

“

Statement of Cash Flows (Topic

230

)

Classification of Certain Cash Receipts and Cash Payments”

(“ASU

No.

2016

15”

). This ASU clarifies and provides specific guidance on

eight

cash flow classification issues that are

not

currently addressed by current GAAP and thereby reduces the current diversity in practice. ASU

No.

2016

is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after

December 15, 2017.

The Company adopted this standard as of

April 1, 2018

with

impact on its consolidated financial statements and related disclosures.

May 2014,

the FASB issued their converged standard on revenue recognition, Accounting Standards Update

No.

2014

09,

“

Revenue from Contracts with Customers (Topic

606

)”

("ASU

No.

2014

09"

), updated in

December 2016

with the release of ASU

2016

20.

August 2015,

the FASB issued ASU

2015

“

Revenue from Contracts with Customers (Topic

606

Deferral of the Effective Date,

" which deferred the effective date of ASU

No.

2014

to annual reporting periods beginning after

December 15, 2017.

April 1, 2018

for contracts that were

not

completed before the adoption date, using the modified retrospective method. The Company has evaluated the effect of the standard and concluded it is

not

have a material effect that requires a retrospective adjustment to any previously reported amounts in the Company’s historical consolidated financial statements for reporting disclosure purposes.

Recently Issued Accounting Pronouncements

July 2018,

the FASB issued ASU

2018

“

Codification Improvements to Topic

842,

Leases

” (“ASU

No.

2018

02”

). This ASU affects narrow aspects of the guidance issued in the amendments in ASU

No.

2016

840,

transition guidance for modifications to leases previously classified as direct financing or sales-type leases under Topic

840,

No.

2016

02.

June 2018,

the FASB issued ASU

2018

“

Compensation - Stock Compensation (Topic

718

)

”

(“ASU

No.

2018

07”

): Improvements to Nonemployee Share-Based Payment Accounting. This ASU expands the scope of Topic

718

No.

2018

is effective for fiscal years beginning after

December 15, 2018,

including interim periods within that fiscal year. Early adoption is permitted but

earlier than an entity’s adoption date of Topic

606.

The Company is currently evaluating the impact this new guidance will have on its financial statements and related disclosures.

February 2016,

the FASB issued ASU

2016

02,

“

Leases (Topic

842

)”

(

“

ASU

No.

2016

02”

). The principle objective of ASU

No.

2016

is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet. ASU

No.

2016

twelve

months. ASU

No.

2016

is effective for fiscal years and interim periods beginning after

December 15, 2018.

Early adoption of ASU

No.

2016

April 1, 2019.

July 2018,

the FASB issued ASU

No.

2018

11,

Leases (Topic

842

): Targeted Improvements

March 2019.

not

expect this guidance to have a material effect on its consolidated results of operations and cash flows.

XML 32 R20.htm IDEA: XBRL DOCUMENT

Note 1 - Significant Accounting Policies (Tables)

3 Months Ended

Jun. 30, 2018

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three months ended June 30, 2018
	Astaxanthin		Spirulina		Total
Packaged products	$	5,095	$	1,068	$	6,163
Bulk products		263		719		982
Total	$	5,358	$	1,787	$	7,145

	Three months ended June 30, 2017
	Astaxanthin		Spirulina		Total
Packaged products	$	5,505	$	1,927	$	7,432
Bulk products		221		1,156		1,377
Total	$	5,726	$	3,083	$	8,809

XML 33 R21.htm IDEA: XBRL DOCUMENT

Note 2 - Inventories (Tables)

3 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	June 30, 201 8		March 31, 201 8
	(in thousands)
Raw materials	$	371	$	410
Work in process		3,301		2,602
Finished goods		5,663		5,878
Supplies		152		144
Inventories, net	$	9,487	$	9,034

XML 34 R22.htm IDEA: XBRL DOCUMENT

Note 3 - Equipment and Leasehold Improvements, Net (Tables)

3 Months Ended

Jun. 30, 2018

Notes Tables

Property, Plant, and Equipment, Estimated Useful Lives [Table Text Block]

	Years
Equipment		3	to	10
Furniture and fixtures		3	to	7
Leasehold improvements		10	to	25

Property, Plant and Equipment [Table Text Block]

	June 30, 201 8			March 31, 201 8
	(in thousands)
Equipment	$	18,114		$	17,935
Leasehold improvements		14,287			14,248
Furniture and fixtures		348			348
		32,749			32,531
Less accumulated depreciation and amortization		(17,821	)		(17,346	)
Construction-in-progress		504			549
Equipment and leasehold improvements, net	$	15,432		$	15,734

XML 35 R23.htm IDEA: XBRL DOCUMENT

Note 5 - Accrued Expenses (Tables)

3 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	June 30, 201 8		March 31, 201 8
	(in thousands)
Wages, commissions, bonus and profit sharing	$	807	$	707
Rent and utilities		69		69
Other accrued expenses		124		116
Total accrued expenses	$	1,000	$	892

XML 36 R24.htm IDEA: XBRL DOCUMENT

Note 6 - Long-term Debt (Tables)

3 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Long-term Debt Instruments [Table Text Block]

	June 30, 201 8			March 31, 201 8
	(in thousands)
Long-term debt	$	6,520		$	6,678
Less current maturities		(660	)		(655	)
Long-term debt, excluding current maturities		5,860			6,023
Less unamortized debt issuance costs		(224	)		(233	)
Total long-term debt, net of current maturities and unamortized debt issuance costs	$	5,636		$	5,790

Schedule of Maturities of Long-term Debt [Table Text Block]

Payments Due	(in thousands)
Next 12 Months	$	660
Year 2		684
Year 3		685
Year 4		716
Year 5		398
Thereafter		3,377
Total principal payments	$	6,520

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 37 R25.htm IDEA: XBRL DOCUMENT

Note 7 - Operating Leases (Tables)

3 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

Payments Due	(in thousands)
Next 12 Months	$	628
Year 2		611
Year 3		537
Year 4		533
Year 5		397
Thereafter		3,741
Total minimum lease payments	$	6,447

XML 38 R26.htm IDEA: XBRL DOCUMENT

Note 9 - Share-based Compensation (Tables)

3 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Share-based Compensation Shares Authorized Available and Outstanding by Plan [Table Text Block]

	As of June 30, 201 8
	Authorized		Available		Outstanding

2016 Plan		1,300,000		1,131,483		152,514
2014 Directors Plan		350,000		231,623		12,000
2005 Plan		—		—		437,400
2004 Directors Plan		—		—		12,000
Total		1,650,000		1,363,106		613,914

Share-based Compensation, Stock Options, Activity [Table Text Block]

Option Activity	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at March 31, 2018		589,400		$	4.06		4.9	$	675,300
Granted		—			—
Exercised		(6,000	)	$	2.85
Forfeited		(2,000	)	$	5.61
Outstanding at June 30, 2018		581,400		$	4.07		4.7	$	158,724
Exercisable at June 30, 2018		461,400		$	4.21		3.6	$	114,324

Schedule of Nonvested Share Activity [Table Text Block]

Nonvested Options	Shares		Weighted Average Grant-Date Fair Value
Nonvested at March 31, 2018		120,000	$	1.81
Granted		—		—
Vested		—		—
Forfeited		—		—
Nonvested at June 30, 2018		120,000	$	1.81

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

			Outstanding Options						Exercisable Options
Range of Exercise Prices			Number of Shares		Remaining Life (Years)		Weighted Average Price		Number of Shares		Weighted Average Price
$1.60	-	$3.70		166,800		5.1	$	3.06		91,800	$	2.82
$3.71	-	$4.42		239,100		4.5		3.83		194,100		3.83
$4.43	-	$5.40		95,000		4.9		5.00		95,000		5.00
$5.41	-	$7.08		80,500		4.4		5.77		80,500		5.77
Total stock options				581,400		4.7	$	4.07		461,400	$	4.21

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	201 8
Exercise Price	$	3.83
Volatility		51.91	%
Risk Free Rate		2.50	%
Vesting Period (years)		3.0
Forfeiture Rate		0.00	%
Expected Life (in years)		6.00
Dividend Rate		0	%

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

Nonvested Restricted Stock Units	Shares			Weighted Average Grant Price
Nonvested restricted stock units at March 31, 2018		39,675		$	3.89
Granted		1,474			5.25
Vested		(7,670	)		3.92
Forfeited		(965	)		4.29
Nonvested restricted stock units at June 30, 2018		32,514		$	3.93

XML 39 R27.htm IDEA: XBRL DOCUMENT

Note 11 - Earnings (Loss) Per Share (Tables)

3 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended June 30, 201 8
	Net Loss (Numerator)			Shares (Denominator)		Per Share Amount
	(in thousands)
Basic and diluted loss per share	$	(1,275	)		5,785	$	(0.22	)

	Three Months Ended June 30, 201 7
	Net Income (Numerator)		Shares (Denominator)		Per Share Amount
	(in thousands)
Basic income per share	$	501		5,685	$	0.09
Effect of dilutive securities-Common stock options		—		34		—
Diluted income per share	$	501		5,719	$	0.09

XML 40 R28.htm IDEA: XBRL DOCUMENT

Note 1 - Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Aug. 30, 2016
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 935,000		$ 1,329,000	$ 1,407,000
Working Capital (Deficit)	6,900,000		7,900,000
Line of Credit, Current	1,250,000		$ 500,000
Deposit Account [Member]
Contract with Customer, Liability, Revenue Recognized	112,000	$ 45,000
First Foundation Bank [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 2,000,000
Line of Credit, Current	1,250,000
Line of Credit Facility, Remaining Borrowing Capacity	750,000
Long-term Debt and Capital Lease Obligations, Current and Noncurrent	$ 6,200,000

XML 41 R29.htm IDEA: XBRL DOCUMENT

Note 1 - Significant Accounting Policies - Revenue By Product (Details) - USD ($) $ in Thousands	3 Months Ended		15 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018
Revenue	$ 7,145	$ 8,809	$ 8,809
Packaged Astaxanthin [Member]
Revenue	5,095		5,505
Packaged Spirulina [Member]
Revenue	1,068		1,927
Packaged Products [Member]
Revenue	6,163		7,432
Bulk Astaxanthin [Member]
Revenue	263		221
Bulk Spirulina [Member]
Revenue	719		1,156
Bulk Products [Member]
Revenue	982		1,377
Astaxanthin [Member]
Revenue	5,358		5,726
Spirulina [Member]
Revenue	$ 1,787		$ 3,083

XML 42 R30.htm IDEA: XBRL DOCUMENT

Note 2 - Inventories (Details Textual) - USD ($)	3 Months Ended
Note 2 - Inventories (Details Textual) - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Inventory Abnormal Production Costs	$ 250,000	$ 0
Non Inventoriable Fixed Costs	$ 125,000	$ 9,000

XML 43 R31.htm IDEA: XBRL DOCUMENT

Note 2 - Inventories - Components of Inventory (Details) - USD ($)
$ in Thousands

Jun. 30, 2018

Mar. 31, 2018

Raw materials

$ 371

$ 410

Work in process

3,301

2,602

Finished goods

^[1]

5,663

5,878

Supplies

152

144

Inventories, net

$ 9,487

$ 9,034

[1]	Net of reserve for obsolescence of $1,000 and $5,000 at June 30, 2018 and March 31, 2018, respectively.

XML 44 R32.htm IDEA: XBRL DOCUMENT

Note 3 - Equipment and Leasehold Improvements, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Asset Impairment Charges, Total	$ 0	$ 0

XML 45 R33.htm IDEA: XBRL DOCUMENT

Note 3 - Equipment and Leasehold Improvements, Net - Estimated Useful Lives (Details)	3 Months Ended
	Jun. 30, 2018
Equipment [Member] \| Minimum [Member]
Estimated useful lives (Year)	3 years
Equipment [Member] \| Maximum [Member]
Estimated useful lives (Year)	10 years
Furniture and Fixtures [Member] \| Minimum [Member]
Estimated useful lives (Year)	3 years
Furniture and Fixtures [Member] \| Maximum [Member]
Estimated useful lives (Year)	7 years
Leasehold Improvements [Member] \| Minimum [Member]
Estimated useful lives (Year)	10 years
Leasehold Improvements [Member] \| Maximum [Member]
Estimated useful lives (Year)	25 years

XML 46 R34.htm IDEA: XBRL DOCUMENT

Note 3 - Equipment and Leasehold Improvements, Net - Components of Equipment and Leasehold Improvements (Details) - USD ($)
$ in Thousands

Jun. 30, 2018

Mar. 31, 2018

Equipment and leasehold improvements, gross

$ 32,749

$ 32,531

Less accumulated depreciation and amortization

(17,821)

(17,346)

Construction-in-progress

504

549

Equipment and leasehold improvements, net

15,432

15,734

Equipment [Member]

Equipment and leasehold improvements, gross

^[1]

18,114

17,935

Leasehold Improvements [Member]

Equipment and leasehold improvements, gross

14,287

14,248

Furniture and Fixtures [Member]

Equipment and leasehold improvements, gross

$ 348

[1]	Includes $373,000 of equipment under capital lease at March 31, 2018 and 2017 respectively, with accumulated amortization of $175,000 and $106,000, respectively.

XML 47 R35.htm IDEA: XBRL DOCUMENT

Note 4 - Line of Credit (Details Textual) - USD ($)	Aug. 30, 2016	Jun. 30, 2018	Mar. 31, 2018
Line of Credit, Current		$ 1,250,000	$ 500,000
First Foundation Bank [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,000,000
Line of Credit, Current		1,250,000
Line of Credit Facility, Remaining Borrowing Capacity		$ 750,000
First Foundation Bank [Member] \| Revolving Credit Facility [Member] \| Prime Rate [Member]
Debt Instrument Reference Rate		5.00%
Debt Instrument, Basis Spread on Variable Rate	2.00%

XML 48 R36.htm IDEA: XBRL DOCUMENT

Note 5 - Accrued Expenses - Components of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018
Wages, commissions, bonus and profit sharing	$ 807	$ 707
Rent and utilities	69	69
Other accrued expenses	124	116
Total accrued expenses	$ 1,000	$ 892

XML 49 R37.htm IDEA: XBRL DOCUMENT

Note 6 - Long-term Debt (Details Textual)				1 Months Ended	3 Months Ended
Note 6 - Long-term Debt (Details Textual)	Oct. 06, 2017 USD ($)	Sep. 18, 2015 USD ($)	Aug. 14, 2012 USD ($)	Jul. 30, 2015 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)
Repayments of Notes Payable		$ 500,000
Long-term Debt, Total					$ 149,000	$ 156,000
Bank of the West Finance [Member]
Capital Leased Assets, Gross, Total					$ 278,000
Debt Instrument Periodic Payments Number					60
Capital Lease Obligations, Total					$ 131,000	148,000
Bank of the West Finance [Member] \| Capital Lease Asses Payable in 36 Equal Monthly Payments [Member]
Debt Instrument Periodic Payments Number					36
Capital Leased Assets, Number of Units					1
Minimum [Member] \| Bank of the West Finance [Member]
Debt Instrument, Interest Rate, Stated Percentage					4.18%
Maximum [Member] \| Bank of the West Finance [Member]
Debt Instrument, Interest Rate, Stated Percentage					12.90%
The 2015 Loan Agreement [Member]
Proceeds from Issuance of Debt				$ 2,500,000
Debt Instrument, Term				7 years
Debt Instrument, Prepayment Penalty Percentage					5.00%
Debt Instrument, Prepayment Penalty Percentage Reduction During Each Year					1.00%
Long-term Debt and Capital Lease Obligations, Current and Noncurrent					$ 1,644,000	1,726,000
Debt Instrument One Time Origination and Guaranty Fees					$ 113,900
Debt Instrument Annual Renewal Fee Payable Percentage					0.50%
Debt Instrument Guaranteed Portion					80.00%
The 2015 Loan Agreement [Member] \| Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage					6.00%
The 2015 Loan Agreement [Member] \| Prime Rate [Member]
Debt Instrument Reference Rate					5.00%
Debt Instrument, Basis Spread on Variable Rate					2.00%
Term Loan Agreement, Maturing on August 14, 2032 [Member]
Proceeds from Issuance of Debt			$ 5,500,000
Debt Instrument Reference Rate					5.00%
Debt Instrument, Basis Spread on Variable Rate			1.00%
Long-term Debt and Capital Lease Obligations, Current and Noncurrent					$ 4,596,000	$ 4,648,000
Debt Instrument One Time Origination and Guaranty Fees			$ 214,500
Debt Instrument Annual Renewal Fee Payable Percentage			0.25%
Debt Instrument Guaranteed Portion			80.00%
Debt Instrument Interest Payment Period			1 year
Debt Instrument Amortization Period			19 years
Term Loan Agreement, Maturing on August 14, 2032 [Member] \| Minimum [Member]
Debt Instrument, Interest Rate During Period			5.50%
Term Loan Agreement, Promissory Note One [Member]
Proceeds from Issuance of Debt			$ 2,250,000
Term Loan Agreement, Promissory Note Two [Member]
Proceeds from Issuance of Debt			$ 3,250,000
Equipment Finance Agreement [Member]
Debt Instrument, Term	5 years
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Debt Agreement, Maximum Borrowing Capacity	$ 175,000

XML 50 R38.htm IDEA: XBRL DOCUMENT

Note 6 - Long-term Debt - Summary of Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018
Total principal payments	$ 6,520	$ 6,678
Less current maturities	(660)	(655)
Long-term debt, excluding current maturities	5,860	6,023
Less unamortized debt issuance costs	(224)	(233)
Total long-term debt, net of current maturities and unamortized debt issuance costs	$ 5,636	$ 5,790

XML 51 R39.htm IDEA: XBRL DOCUMENT

Note 6 - Long-term Debt - Future Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018
Next 12 Months	$ 660
Year 2	684
Year 3	685
Year 4	716
Year 5	398
Thereafter	3,377
Total principal payments	$ 6,520	$ 6,678

XML 52 R40.htm IDEA: XBRL DOCUMENT

Note 7 - Operating Leases - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details) $ in Thousands	Jun. 30, 2018 USD ($)
Next 12 Months	$ 628
Year 2	611
Year 3	537
Year 4	533
Year 5	397
Thereafter	3,741
Total minimum lease payments	$ 6,447

XML 53 R41.htm IDEA: XBRL DOCUMENT

Note 9 - Share-based Compensation (Details Textual)		1 Months Ended	3 Months Ended
Note 9 - Share-based Compensation (Details Textual)	Apr. 05, 2018 $ / shares shares	Aug. 01, 2018 shares	Jun. 30, 2018 USD ($) $ / shares shares	Jun. 30, 2017 USD ($)	Aug. 25, 2016 shares	Aug. 28, 2014 shares
Number of Shareholder Approved Share-based Compensation Plans			2
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			1,363,106
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			1,650,000
Share Price \| $ / shares			$ 3.90
Employee Stock Option [Member]
Allocated Share-based Compensation Expense, Total \| $			$ 18,000	$ 15,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total \| $			$ 163,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years
Restricted Stock Units (RSUs) [Member]
Allocated Share-based Compensation Expense, Total \| $			$ 16,000	$ 16,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total \| $			$ 110,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 292 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			1,474
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares			$ 5.25
Restricted Stock Units (RSUs) [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	1,474
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares	$ 5.25
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	2 years
Maximum [Member] \| Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
The 2005 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
The 2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			1,131,483
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					1,300,000
The 2016 Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			1,131,483
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			1,300,000
The 2016 Plan [Member] \| Restricted Stock Units (RSUs) [Member] \| Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		22,449
The 2016 Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized for Issuance in Connection with Performance Awards and Stock Awards					600,000
2014 Directors Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			231,623
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			350,000			350,000
2004 Directors Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

XML 54 R42.htm IDEA: XBRL DOCUMENT

Note 9 - Share-based Compensation - Shares Authorized, Available for Future Grant and Outstanding Under Each Plan (Details) - shares	Jun. 30, 2018	Mar. 31, 2018	Aug. 25, 2016	Aug. 28, 2014
Authorized (in shares)	1,650,000
Available (in shares)	1,363,106
Outstanding (in shares)	613,914
Restricted Stock Units (RSUs) [Member]
Outstanding (in shares)	32,514	39,675
The 2016 Plan [Member]
Authorized (in shares)			1,300,000
Available (in shares)	1,131,483
The 2016 Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Authorized (in shares)	1,300,000
Available (in shares)	1,131,483
Outstanding (in shares)	152,514
2014 Directors Plan [Member]
Authorized (in shares)	350,000			350,000
Available (in shares)	231,623
Outstanding (in shares)	12,000
The 2005 Plan [Member]
Authorized (in shares)
Available (in shares)	0
Outstanding (in shares)	437,400
2004 Directors Plan [Member]
Authorized (in shares)
Available (in shares)	0
Outstanding (in shares)	12,000

XML 55 R43.htm IDEA: XBRL DOCUMENT

Note 9 - Share-based Compensation - Summary of Option Activity Under Stock Plans (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Outstanding (in shares)	589,400
Outstanding, weighted average exercise price (in dollars per share)	$ 4.06
Outstanding, weighted average remaining contractual term (Year)	4 years 255 days	4 years 328 days
Outstanding, aggregate intrinsic value	$ 158,724	$ 675,300
Granted (in shares)
Granted, weighted average exercise price (in dollars per share)
Exercised (in shares)	(6,000)
Exercised, weighted average exercise price (in dollars per share)	$ 2.85
Forfeited (in shares)	(2,000)
Forfeited, weighted average exercise price (in dollars per share)	$ 5.61
Outstanding (in shares)	581,400	589,400
Outstanding, weighted average exercise price (in dollars per share)	$ 4.07	$ 4.06
Exercisable (in shares)	461,400
Exercisable, weighted average exercise price (in dollars per share)	$ 4.21
Exercisable, weighted average remaining contractual term (Year)	3 years 219 days
Exercisable, aggregate intrinsic value	$ 114,324

XML 56 R44.htm IDEA: XBRL DOCUMENT

Note 9 - Share-based Compensation - Summary of Non-vested Options (Details)	3 Months Ended
	Jun. 30, 2018 $ / shares shares
Nonvested (in shares) \| shares	120,000
Granted (in shares) \| shares
Vested (in shares) \| shares
Forfeited (in shares) \| shares
Nonvested (in shares) \| shares	120,000
Nonvested (in dollars per share) \| $ / shares	$ 1.81
Granted (in dollars per share) \| $ / shares
Vested (in dollars per share) \| $ / shares
Forfeited (in dollars per share) \| $ / shares
Nonvested (in dollars per share) \| $ / shares	$ 1.81

XML 57 R45.htm IDEA: XBRL DOCUMENT

Note 9 - Share-based Compensation - Summary of the Weighted-average Characteristics of Outstanding Stock Options (Details)	3 Months Ended
	Jun. 30, 2018 $ / shares shares
Outstanding Options Number of Shares (in shares) \| shares	581,400
Outstanding Options Remaining Life (Year)	4 years 255 days
Outstanding Options Weighted Average Price (in dollars per share)	$ 4.07
Exercisable Options Number of Shares (in shares) \| shares	461,400
Exercisable Options Weighted Average Price (in dollars per share)	$ 4.21
Range 01 [Member]
Lower Range of Exercise (in dollars per share)	1.60
Upper Range of Exercise (in dollars per share)	$ 3.70
Outstanding Options Number of Shares (in shares) \| shares	166,800
Outstanding Options Remaining Life (Year)	5 years 36 days
Outstanding Options Weighted Average Price (in dollars per share)	$ 3.06
Exercisable Options Number of Shares (in shares) \| shares	91,800
Exercisable Options Weighted Average Price (in dollars per share)	$ 2.82
Range 02 [Member]
Lower Range of Exercise (in dollars per share)	3.71
Upper Range of Exercise (in dollars per share)	$ 4.42
Outstanding Options Number of Shares (in shares) \| shares	239,100
Outstanding Options Remaining Life (Year)	4 years 182 days
Outstanding Options Weighted Average Price (in dollars per share)	$ 3.83
Exercisable Options Number of Shares (in shares) \| shares	194,100
Exercisable Options Weighted Average Price (in dollars per share)	$ 3.83
Range 03 [Member]
Lower Range of Exercise (in dollars per share)	4.43
Upper Range of Exercise (in dollars per share)	$ 5.40
Outstanding Options Number of Shares (in shares) \| shares	95,000
Outstanding Options Remaining Life (Year)	4 years 328 days
Outstanding Options Weighted Average Price (in dollars per share)	$ 5
Exercisable Options Number of Shares (in shares) \| shares	95,000
Exercisable Options Weighted Average Price (in dollars per share)	$ 5
Range 04 [Member]
Lower Range of Exercise (in dollars per share)	5.41
Upper Range of Exercise (in dollars per share)	$ 7.08
Outstanding Options Number of Shares (in shares) \| shares	80,500
Outstanding Options Remaining Life (Year)	4 years 146 days
Outstanding Options Weighted Average Price (in dollars per share)	$ 5.77
Exercisable Options Number of Shares (in shares) \| shares	80,500
Exercisable Options Weighted Average Price (in dollars per share)	$ 5.77

XML 58 R46.htm IDEA: XBRL DOCUMENT

Note 9 - Share-based Compensation - Summary of Valuation Assumptions Related to Options Granted (Details)	3 Months Ended
	Jun. 30, 2018 $ / shares
Exercise Price (in dollars per share)	$ 3.83
Volatility	51.91%
Risk Free Rate	2.50%
Vesting Period (years) (Year)	3 years
Forfeiture Rate	0.00%
Expected Life (in years) (Year)	6 years
Dividend Rate	0.00%

XML 59 R47.htm IDEA: XBRL DOCUMENT

Note 9 - Share-based Compensation - Restricted Stock Units (Details)	3 Months Ended
	Jun. 30, 2018 $ / shares shares
Nonvested restricted stock units at March 31, 2018 (in shares)
Nonvested restricted stock units at June 30, 2018 (in shares)	613,914
Restricted Stock Units (RSUs) [Member]
Nonvested restricted stock units at March 31, 2018 (in shares)	39,675
Granted (in shares)	1,474
Vested (in shares)	(7,670)
Forfeited (in shares)	(965)
Nonvested restricted stock units at June 30, 2018 (in shares)	32,514
Nonvested restricted stock units at March 31, 2017, weighted average grant price (in dollars per share) \| $ / shares	$ 3.89
Granted, weighted average grant price (in dollars per share) \| $ / shares	5.25
Vested, weighted average grant price (in dollars per share) \| $ / shares	3.92
Forfeited, weighted average grant price (in dollars per share) \| $ / shares	4.29
Nonvested restricted stock units at March 31, 2018, weighted average grant price (in dollars per share) \| $ / shares	$ 3.93

XML 60 R48.htm IDEA: XBRL DOCUMENT

Note 10 - Income Taxes (Details Textual) - USD ($)	3 Months Ended
Note 10 - Income Taxes (Details Textual) - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability	$ (22,000)	$ 11,000
Effective Income Tax Rate Reconciliation, Percent, Total	1.70%	2.10%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Unrecognized Tax Benefits, Ending Balance	$ 0

XML 61 R49.htm IDEA: XBRL DOCUMENT

Note 11 - Earnings (Loss) Per Share (Details Textual) - shares	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	120,000	0
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,206	27,344

XML 62 R50.htm IDEA: XBRL DOCUMENT

Note 11 - Earnings (Loss) Per Share - Summary of Reconciliations Between the Numerator and the Denominator of the Basic and Diluted Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Net income (loss)	$ (1,275)	$ 501
Shares outstanding - basic and diluted (in shares)	5,785
Earnings per share - basic and diluted (in dollars per share)	$ (0.22)
Net (loss) income	$ (1,275)	$ 501
Shares outstanding - basic (in shares)	5,785	5,685
Earnings per share - basic (in dollars per share)	$ (0.22)	$ 0.09
Effect of dilutive securities on net income
Shares - dilutive securities (in shares)		34
Net income - diluted		$ 501
Shares outstanding - diluted (in shares)	5,785	5,719
Earnings per share - diluted (in dollars per share)	$ (0.22)	$ 0.09

XML 63 R51.htm IDEA: XBRL DOCUMENT

Note 12 - Concentrations of Risk (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018
Accounts Receivable [Member]
Concentration Risk, Percentage	79.00%		77.00%
Number of Major Customers	2		3
Accounts Receivable [Member] \| Customer Number 2 [Member]
Concentration Risk, Percentage	42.00%		17.00%
Accounts Receivable [Member] \| Customer Number 1 [Member]
Concentration Risk, Percentage	37.00%		49.00%
Accounts Receivable [Member] \| Customer Number 3 [Member]
Concentration Risk, Percentage			11.00%
Sales Revenue, Net [Member]
Number of Major Customers	2	2
Sales Revenue, Net [Member] \| Customer Number 2 [Member]
Concentration Risk, Percentage	27.00%	13.00%
Sales Revenue, Net [Member] \| Customer Number 1 [Member]
Concentration Risk, Percentage	31.00%	32.00%

XML 64 R52.htm IDEA: XBRL DOCUMENT

Note 13 - Related Party Transactions and Balances (Details Textual) - Director [Member]	3 Months Ended
	Jun. 30, 2018 USD ($)
Due to Related Parties, Total	$ 120,000
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party	$ 46,000

EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 66 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 112 241 1 true 45 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.cyanotech.com/20180630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.cyanotech.com/20180630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.cyanotech.com/20180630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.cyanotech.com/20180630/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.cyanotech.com/20180630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Disclosure - Note 1 - Significant Accounting Policies Sheet http://www.cyanotech.com/20180630/role/statement-note-1-significant-accounting-policies Note 1 - Significant Accounting Policies Notes 6 false false R7.htm 006 - Disclosure - Note 2 - Inventories Sheet http://www.cyanotech.com/20180630/role/statement-note-2-inventories Note 2 - Inventories Notes 7 false false R8.htm 007 - Disclosure - Note 3 - Equipment and Leasehold Improvements, Net Sheet http://www.cyanotech.com/20180630/role/statement-note-3-equipment-and-leasehold-improvements-net Note 3 - Equipment and Leasehold Improvements, Net Notes 8 false false R9.htm 008 - Disclosure - Note 4 - Line of Credit Sheet http://www.cyanotech.com/20180630/role/statement-note-4-line-of-credit Note 4 - Line of Credit Notes 9 false false R10.htm 009 - Disclosure - Note 5 - Accrued Expenses Sheet http://www.cyanotech.com/20180630/role/statement-note-5-accrued-expenses Note 5 - Accrued Expenses Notes 10 false false R11.htm 010 - Disclosure - Note 6 - Long-term Debt Sheet http://www.cyanotech.com/20180630/role/statement-note-6-longterm-debt Note 6 - Long-term Debt Notes 11 false false R12.htm 011 - Disclosure - Note 7 - Operating Leases Sheet http://www.cyanotech.com/20180630/role/statement-note-7-operating-leases Note 7 - Operating Leases Notes 12 false false R13.htm 012 - Document - Note 8 - Other Commitments and Contingencies Sheet http://www.cyanotech.com/20180630/role/statement-note-8-other-commitments-and-contingencies Note 8 - Other Commitments and Contingencies Uncategorized 13 false false R14.htm 013 - Disclosure - Note 9 - Share-based Compensation Sheet http://www.cyanotech.com/20180630/role/statement-note-9-sharebased-compensation Note 9 - Share-based Compensation Uncategorized 14 false false R15.htm 014 - Disclosure - Note 10 - Income Taxes Sheet http://www.cyanotech.com/20180630/role/statement-note-10-income-taxes Note 10 - Income Taxes Uncategorized 15 false false R16.htm 015 - Disclosure - Note 11 - Earnings (Loss) Per Share Sheet http://www.cyanotech.com/20180630/role/statement-note-11-earnings-loss-per-share Note 11 - Earnings (Loss) Per Share Uncategorized 16 false false R17.htm 016 - Disclosure - Note 12 - Concentrations of Risk Sheet http://www.cyanotech.com/20180630/role/statement-note-12-concentrations-of-risk Note 12 - Concentrations of Risk Uncategorized 17 false false R18.htm 017 - Disclosure - Note 13 - Related Party Transactions and Balances Sheet http://www.cyanotech.com/20180630/role/statement-note-13-related-party-transactions-and-balances Note 13 - Related Party Transactions and Balances Uncategorized 18 false false R19.htm 018 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.cyanotech.com/20180630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Uncategorized 19 false false R20.htm 019 - Disclosure - Note 1 - Significant Accounting Policies (Tables) Sheet http://www.cyanotech.com/20180630/role/statement-note-1-significant-accounting-policies-tables Note 1 - Significant Accounting Policies (Tables) Uncategorized 20 false false R21.htm 020 - Disclosure - Note 2 - Inventories (Tables) Sheet http://www.cyanotech.com/20180630/role/statement-note-2-inventories-tables Note 2 - Inventories (Tables) Uncategorized 21 false false R22.htm 021 - Disclosure - Note 3 - Equipment and Leasehold Improvements, Net (Tables) Sheet http://www.cyanotech.com/20180630/role/statement-note-3-equipment-and-leasehold-improvements-net-tables Note 3 - Equipment and Leasehold Improvements, Net (Tables) Uncategorized 22 false false R23.htm 022 - Disclosure - Note 5 - Accrued Expenses (Tables) Sheet http://www.cyanotech.com/20180630/role/statement-note-5-accrued-expenses-tables Note 5 - Accrued Expenses (Tables) Uncategorized 23 false false R24.htm 023 - Disclosure - Note 6 - Long-term Debt (Tables) Sheet http://www.cyanotech.com/20180630/role/statement-note-6-longterm-debt-tables Note 6 - Long-term Debt (Tables) Uncategorized 24 false false R25.htm 024 - Disclosure - Note 7 - Operating Leases (Tables) Sheet http://www.cyanotech.com/20180630/role/statement-note-7-operating-leases-tables Note 7 - Operating Leases (Tables) Uncategorized 25 false false R26.htm 025 - Disclosure - Note 9 - Share-based Compensation (Tables) Sheet http://www.cyanotech.com/20180630/role/statement-note-9-sharebased-compensation-tables Note 9 - Share-based Compensation (Tables) Uncategorized 26 false false R27.htm 026 - Disclosure - Note 11 - Earnings (Loss) Per Share (Tables) Sheet http://www.cyanotech.com/20180630/role/statement-note-11-earnings-loss-per-share-tables Note 11 - Earnings (Loss) Per Share (Tables) Uncategorized 27 false false R28.htm 027 - Disclosure - Note 1 - Significant Accounting Policies (Details Textual) Sheet http://www.cyanotech.com/20180630/role/statement-note-1-significant-accounting-policies-details-textual Note 1 - Significant Accounting Policies (Details Textual) Uncategorized 28 false false R29.htm 028 - Disclosure - Note 1 - Significant Accounting Policies - Revenue By Product (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-1-significant-accounting-policies-revenue-by-product-details Note 1 - Significant Accounting Policies - Revenue By Product (Details) Uncategorized 29 false false R30.htm 029 - Disclosure - Note 2 - Inventories (Details Textual) Sheet http://www.cyanotech.com/20180630/role/statement-note-2-inventories-details-textual Note 2 - Inventories (Details Textual) Uncategorized 30 false false R31.htm 030 - Disclosure - Note 2 - Inventories - Components of Inventory (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-2-inventories-components-of-inventory-details Note 2 - Inventories - Components of Inventory (Details) Uncategorized 31 false false R32.htm 031 - Disclosure - Note 3 - Equipment and Leasehold Improvements, Net (Details Textual) Sheet http://www.cyanotech.com/20180630/role/statement-note-3-equipment-and-leasehold-improvements-net-details-textual Note 3 - Equipment and Leasehold Improvements, Net (Details Textual) Uncategorized 32 false false R33.htm 032 - Disclosure - Note 3 - Equipment and Leasehold Improvements, Net - Estimated Useful Lives (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-3-equipment-and-leasehold-improvements-net-estimated-useful-lives-details Note 3 - Equipment and Leasehold Improvements, Net - Estimated Useful Lives (Details) Uncategorized 33 false false R34.htm 033 - Disclosure - Note 3 - Equipment and Leasehold Improvements, Net - Components of Equipment and Leasehold Improvements (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-3-equipment-and-leasehold-improvements-net-components-of-equipment-and-leasehold-improvements-details Note 3 - Equipment and Leasehold Improvements, Net - Components of Equipment and Leasehold Improvements (Details) Uncategorized 34 false false R35.htm 034 - Disclosure - Note 4 - Line of Credit (Details Textual) Sheet http://www.cyanotech.com/20180630/role/statement-note-4-line-of-credit-details-textual Note 4 - Line of Credit (Details Textual) Uncategorized 35 false false R36.htm 035 - Disclosure - Note 5 - Accrued Expenses - Components of Accrued Expenses (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-5-accrued-expenses-components-of-accrued-expenses-details Note 5 - Accrued Expenses - Components of Accrued Expenses (Details) Uncategorized 36 false false R37.htm 036 - Disclosure - Note 6 - Long-term Debt (Details Textual) Sheet http://www.cyanotech.com/20180630/role/statement-note-6-longterm-debt-details-textual Note 6 - Long-term Debt (Details Textual) Uncategorized 37 false false R38.htm 037 - Disclosure - Note 6 - Long-term Debt - Summary of Long-term Debt (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-6-longterm-debt-summary-of-longterm-debt-details Note 6 - Long-term Debt - Summary of Long-term Debt (Details) Uncategorized 38 false false R39.htm 038 - Disclosure - Note 6 - Long-term Debt - Future Payments (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-6-longterm-debt-future-payments-details Note 6 - Long-term Debt - Future Payments (Details) Uncategorized 39 false false R40.htm 039 - Disclosure - Note 7 - Operating Leases - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-7-operating-leases-summary-of-future-minimum-lease-payments-under-noncancelable-operating-leases-details Note 7 - Operating Leases - Summary of Future Minimum Lease Payments Under Non-cancelable Operating Leases (Details) Uncategorized 40 false false R41.htm 040 - Disclosure - Note 9 - Share-based Compensation (Details Textual) Sheet http://www.cyanotech.com/20180630/role/statement-note-9-sharebased-compensation-details-textual Note 9 - Share-based Compensation (Details Textual) Uncategorized 41 false false R42.htm 041 - Disclosure - Note 9 - Share-based Compensation - Shares Authorized, Available for Future Grant and Outstanding Under Each Plan (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-9-sharebased-compensation-shares-authorized-available-for-future-grant-and-outstanding-under-each-plan-details Note 9 - Share-based Compensation - Shares Authorized, Available for Future Grant and Outstanding Under Each Plan (Details) Uncategorized 42 false false R43.htm 042 - Disclosure - Note 9 - Share-based Compensation - Summary of Option Activity Under Stock Plans (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-9-sharebased-compensation-summary-of-option-activity-under-stock-plans-details Note 9 - Share-based Compensation - Summary of Option Activity Under Stock Plans (Details) Uncategorized 43 false false R44.htm 043 - Disclosure - Note 9 - Share-based Compensation - Summary of Non-vested Options (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-9-sharebased-compensation-summary-of-nonvested-options-details Note 9 - Share-based Compensation - Summary of Non-vested Options (Details) Uncategorized 44 false false R45.htm 044 - Disclosure - Note 9 - Share-based Compensation - Summary of the Weighted-average Characteristics of Outstanding Stock Options (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-9-sharebased-compensation-summary-of-the-weightedaverage-characteristics-of-outstanding-stock-options-details Note 9 - Share-based Compensation - Summary of the Weighted-average Characteristics of Outstanding Stock Options (Details) Uncategorized 45 false false R46.htm 045 - Disclosure - Note 9 - Share-based Compensation - Summary of Valuation Assumptions Related to Options Granted (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-9-sharebased-compensation-summary-of-valuation-assumptions-related-to-options-granted-details Note 9 - Share-based Compensation - Summary of Valuation Assumptions Related to Options Granted (Details) Uncategorized 46 false false R47.htm 046 - Disclosure - Note 9 - Share-based Compensation - Restricted Stock Units (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-9-sharebased-compensation-restricted-stock-units-details Note 9 - Share-based Compensation - Restricted Stock Units (Details) Uncategorized 47 false false R48.htm 047 - Disclosure - Note 10 - Income Taxes (Details Textual) Sheet http://www.cyanotech.com/20180630/role/statement-note-10-income-taxes-details-textual Note 10 - Income Taxes (Details Textual) Uncategorized 48 false false R49.htm 048 - Disclosure - Note 11 - Earnings (Loss) Per Share (Details Textual) Sheet http://www.cyanotech.com/20180630/role/statement-note-11-earnings-loss-per-share-details-textual Note 11 - Earnings (Loss) Per Share (Details Textual) Uncategorized 49 false false R50.htm 049 - Disclosure - Note 11 - Earnings (Loss) Per Share - Summary of Reconciliations Between the Numerator and the Denominator of the Basic and Diluted Earnings Per Share Computations (Details) Sheet http://www.cyanotech.com/20180630/role/statement-note-11-earnings-loss-per-share-summary-of-reconciliations-between-the-numerator-and-the-denominator-of-the-basic-and-diluted-earnings-per-share-computations-details Note 11 - Earnings (Loss) Per Share - Summary of Reconciliations Between the Numerator and the Denominator of the Basic and Diluted Earnings Per Share Computations (Details) Uncategorized 50 false false R51.htm 050 - Disclosure - Note 12 - Concentrations of Risk (Details Textual) Sheet http://www.cyanotech.com/20180630/role/statement-note-12-concentrations-of-risk-details-textual Note 12 - Concentrations of Risk (Details Textual) Uncategorized 51 false false R52.htm 051 - Disclosure - Note 13 - Related Party Transactions and Balances (Details Textual) Sheet http://www.cyanotech.com/20180630/role/statement-note-13-related-party-transactions-and-balances-details-textual Note 13 - Related Party Transactions and Balances (Details Textual) Uncategorized 52 false false All Reports Book All Reports cyan-20180630.xml cyan-20180630.xsd cyan-20180630_cal.xml cyan-20180630_def.xml cyan-20180630_lab.xml cyan-20180630_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 71 0001437749-18-015344-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-18-015344-xbrl.zip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end